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ABSTRACT 
Enzyme Catalyzed Synthesis of Structured Phospholipids with Conjugated Linoleic Acid 
and Plant Sterols. (May 2005) 
Md. Monjur Hossen, B.Tech., Indian Institute of Technology; 
M.E., Asian Institute of Technology 
Co-Chairs of Advisory Committee: Dr. Ernesto Hernandez 
                                                        Dr. Lloyd W. Rooney  
 
 
 
Structured phospholipids with functional ingredients like conjugated linoleic acid 
(CLA) and plant sterols to deliver their physiological effects in different food 
formulations were synthesized. The lipase and phospholipase A2 catalyzed enzymatic 
acidolysis reaction between phospholipids (PLs) and CLA was used for fatty acid 
modification, while the phospholipase D catalyzed transphosphatidylation reaction 
between PLs and sterol was used for head group modification. Enzymatic processes 
were an effective way to produce structured phospholipids. Screening of four lipases and 
immobilized phospholipase A2 and combination of lipase and phospholipase showed that 
only Lipozyme RM IM and Lipozyme TL IM were effective in incorporation of CLA 
into PLs. The maximum incorporation achieved by the latter enzyme was 16% with soy 
PLs in 72 h. The class of phospholipids had a significant effect on the rate of 
incorporation of CLA compare to source of PLs. A method capable of predicting the rate 
of incorporation of CLA into phospholipids was developed using response surface 
methodology. A three-level four-factor Central Composite Rotatable Design (CCRD) 
was used. The four factors selected were lipase dosage (Ed, wt.% of substrate), substrate 
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ratio (Sr,mol%), reaction time (ti, h) and reaction temperature (Te,oC). The enzyme load 
and substrate ratio had a greater effect on the rate of incorporation than did reaction time 
and temperature. A polynomial regression equation was developed to predict the 
reaction rate. The new phosphatidyl derivative, phosphatidyl-sitosterol, was found to be 
synthesized by the transfer reaction of phosphatidyl residue from phosphatidylcholine to 
β-sitosterol by phospholipase D from Streptomyces sp. in biphasic medium. The novel 
phosphatidyl sitosterol derivative was identified by MALDI-TOF mass spectrometry. 
Plant sterols were modified to a more polar lipid class by synthesizing phospholipid 
derivatives of them. When these structured phospholipids were added to a whey protein 
based oil-in-water emulsion, the CLA incorporated structured phospholipids (CLA-PL) 
had higher heat stability and oxidative stability compared to the controls. 
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CHAPTER I 
 
 
INTRODUCTION 
 
There is an increasing need to develop functional and nutraceutical foods with 
special characteristics that improve, treat or prevent disease. The global conventional 
food sector has an expected growth rate of 1-3%, but functional food has an anticipated 
growth rate of 7-8% through 2010 (Timmermann 2002). Functional attributes of 
different components such as carotenoids, dietary fiber, omega-3 fatty acids, medium 
chain triglycerides (MCT), conjugated linoleic acid (CLA), polyphenolics, phytosterols, 
and tocotrienols are documented. Food supplements are less desirable than food as a 
source of nutrients, nutraceuticals, and phytochemicals.  
Far better approach would be to design functional and nutritional foods enriched 
with these functional ingredients. Now researchers are trying to establish the most 
effective but versatile delivery system of these functional ingredients to increase their 
bioavailability and chemopreventive effect. 
Phospholipids may be efficient dietary fractions to deliver these functional 
components. There is an increasing interest in the use of phospholipids as natural 
emulsifiers, wetting agents, and dispersal agents in foods, cosmetics, and 
pharmaceuticals. Phospholipids with specific fatty acids and/or polar head groups are 
desirable. We incorporated CLA fatty acids and plant sterols into phospholipid to  
 
____________________________________ 
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produce novel phospholipid-conjugates suitable for use as nutaceuticals or as functional 
food ingredients.  
There have been many reports on phospholipid acyl exchange and polar head 
group modification (Chamiel and others 1999, Mustranta and others 1994a, Aura and 
others 1995). Fatty acids might be more easily digested as phospholipids than as 
triacylglycerols or esters, especially when the fatty acids are situated on the sn-2 position 
of phospholipids (Hallberg and Härröd 1994). Carnielli and others (1998) reported 
greater absorption of long chain polyunsaturated fatty acids from phospholipids 
compared to triacylglycerols for infant formula.  
1.1 Enzyme catalyzed synthesis of structured phospholipids with CLA  
Conjugated linoleic acid (CLA) is a generic term for geometric and positional 
isomers of linoleic acid. It is a family of fatty acids rather than a single molecular entity. 
CLA has been reported to have effects in diverse biological functions including: 
anticarcinogenesis, antiatherogenicity, fatty acid metabolism, immune function, and 
bone metabolism (Doyle 1998, Reany and others 2002, Scimeca and others 1994). 
CLAs in foods are quantitatively minor; hence, their consumption by humans is only 
0.5-1 g/d/person (McGuire and others 1999). This current intake is insufficient to meet 
potential biological needs. Ip and others (1994) estimated, on the basis of a rat model, 
that a 70 kg human should consume 3.0 g CLA/day to obtain its beneficial effects. An 
alternative method is to increase CLA content in eggs, milk, and meat by feeding CLA 
to chickens and cows. But Chouinard and others (1999) reported that cows receiving 
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exogenous CLA increased its content in milk but had reduced milk fat yield with a 
change in fatty acid composition.  
The use of CLA as free fatty acids in foods and pharmaceutical products is 
limited. So, CLA incorporated into triacylglycerols and phospholipids may offer 
advantages. Incorporation of CLA into triacylglycerols has been done (Torres and others 
2002, Nagao and others 2002, Won-Seck and others 2000, Garcia and others 1998, 
Arcos and others 1998, McNeil and others 1999). But no reports have been published on 
incorporation of CLA into phospholipids for different types of food and pharmaceutical 
products. Also, the mechanism of CLA function in anticarcinogenesis has not been 
confirmed. This is possibly due to antioxidant activity (Ha and others 1990, Ip and 
others 1991). Ip and others (1991) reported that mammary tumors in rats and mouse 
forestomach neoplasia were suppressed by CLA isomers. They suggested that CLA 
incorporated into phospholipids were active form of CLA isomers. They also postulated 
that the preferential incorporation of cis-9, trans-11 isomer of CLA into membrane 
phospholipid was related to the signal transduction pathway on cell proliferation. Pariza 
and Ha (1991) in their US patent claimed CLA was an effective antioxidant and mold 
growth inhibitor. CLA esterified in phospholipid was more effective as an antioxidant. 
However, several studies (Banni and others 1998, Van den Berg and others 1995) were 
undertaken to reinvestigate the antioxidant property of CLA related to the efficacy in 
cancer prevention and the authors believed that the anticarcinogenesis of CLA was not 
due to antioxidant activity. Since, there are no clinical studies with CLA containing 
phospholipids; our newly produced dietary form of CLA containing phospholipids might 
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explain the mechanism of bioactivity of CLA isomers. This part of the study was 
focused on production of structured phospholipids with modified fatty acid composition 
by enzyme-catalyzed synthesis of CLA containing phospholipids. 
Specific objectives were: 
1) Determine the enzyme or combination of enzymes required to 
produce CLA containing structured phospholipids. 
2) Incorporation of CLA into phospholipids from two different 
sources namely soybean and egg yolk. 
3) Optimize reaction parameters such as enzyme load, reaction 
time, substrate molar ratio and temperature for the production 
of CLA containing phospholipids. 
4) Study the physiological properties of CLA containing 
phospholipids and determining their applications in foods. 
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1.2 Enzyme catalyzed synthesis of structured phospholipids with plant 
sterols 
Phytosterols, which are structurally related to cholesterol but differ in their 
nuclear and/or side chain configuration or polar groups, are claimed to be effective in 
lowering plasma total and LDL cholesterol. The cholesterol lowering effect of plant 
sterols (phytosterols) has been studied since the 1950s (Pollak 1953). But, because of 
poor solubility and bioavailability, doses as high as 25g/day were required for efficacy. 
The crystalline nature and poor solubility of free phytosterols limit their application in 
foods. The enrichment of margarine with plant sterol or stanol ester is a recent 
development in functional foods. The spread supplemented with 8-10% plant sterol 
lowers serum total cholesterol and LDL cholesterol by 8-13% (Weststrate and Meijer 
1998; Hendrinks and others 1999). This is equivalent to the consumption of 1.6-2.0 g of 
plant sterols per day. In an efficacy study on plant stanols, daily consumption of 24 g of 
spread containing 2-3 g of plant stanol esters lowered total serum cholesterol and LDL 
cholesterol by 6.4% and 10.1% respectively (Nguyen and others 1999). However, their 
intestinal bioavailability was still limited. Phytosterols are highly hydrophobic and do 
not dissolve in the micelles of the digestive tract. Therefore, they are incapable of 
efficiently blocking cholesterol absorption. Richard and others found that sitostanol 
reduces cholesterol absorption at doses much lower than reported previously when 
administered in lecithin micelles (1999). So, it is desirable to develop biologically 
effective phytosterols that are effective at lowering plasma cholesterol at lower doses 
and that can also be added to a variety of foods. A hydrophilic phytosterol composed of 
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sitosterol- and campesterol-ascorbyl-phosphate had 15-fold greater cholesterol inhibition 
activity than free sterol (Ramaswamy and others 2002). An aqueous dispersible sterol 
product was invented for beverage applications (Stevens and Schmelzer 2003) and it has 
been reported that orange juice fortified with these plant sterols were effective in 
reducing LDL cholesterol (Devaraj and others 2004). In our present study, synthesis of 
phospholipid derivative of plant sterols is proposed based on these findings. We 
attempted to produce amphiphilic lipids by synthesizing phospholipid containing plant 
sterol amenable to formulation as component of different functional foods. The targeted 
health claim is therapeutic cholesterol lowering.  
This part of the study was focused on production of structured phospholipids 
with modified polar head group by enzyme-catalyzed synthesis of phospholipd-
phytosterol conjugates. 
Specific objective was: 
1) Study the enzymatic transphosphatidyl reaction by 
phospholipase D (PLD) for production of phospholipid-
phytosterol conjugate. 
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CHAPTER II 
 
 
     LITERATURE REVIEW: SYNTHESIS OF STRUCTURED  
PHOSPHOLIPIDS WITH CLA 
 
 
 
2.1 Phospholipids 
 
More than one hundred fifty years have passed since lecithin was identified by 
Mauric Gobley in egg yolk. Lecithin is a term derived from the Greek word lekithos 
(egg yolk) (Wendel 2000). Today, lecithin is described as mixtures of several 
phosphorus containing substances collectively known as phospholipids-present in cell 
membranes of animals and plants. Crude lecithins are mixture of oil and phospholipids 
with minor amounts of other substances and usually prepared from the oil de-gumming 
process. Phospholipids are functional ingredients of lecithin. They have amphiphillic 
molecular structure with a lipophillic part from two fatty acids attached and a 
hydrophilic group from phosphoric acid ester. Phospholipids are determined by the type 
of substance linked to the phosphate group (Figure 1). 
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Figure 1- Structure of glycerophospholipids. R1 and R2 are fatty acids attached to 
phospholipids. 
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2.1.1 Modifications of phospholipids 
 The compositional variety of phospholipids in native lecithin is limited. But, it is 
possible to produce structurally divergent phospholipids with modified head group and 
fatty acids compositions. These structured phospholipids can be tested for their 
functional properties and uses in food products. As part of the modification techniques, 
methods containing physical, chemical and enzymatic processes were used for 
phospholipid modification (Doig and Diks 2003a). Enzymatic modification of 
phospholipids had a clear advantage over chemical and physical techniques. Several 
enzymatic pathways were described (Figure 2) by DArrigo and Servi (1997) for 
preparation of natural and synthetic phospholipids for applications in pharmaceuticals, 
food additives, cosmetics, in liposome technology and in gene therapy.  
 
2.1.1.1 Fatty acids modification of phospholipids 
 The use of lipase and phospholipase enzymes allow the specific 
removal/replacement of the acyl chains at positions sn-1 and sn-2 of phospholipids via 
hydrolysis and subsequent reesterification or through direct interesterification with an 
acyl donor (Mustranta and others 1994b). Lipases can be used to selectively exchange 
fatty acids in the sn-1 position and phospholipase A2 can be used for the corresponding 
selective exchange reaction at sn-2 position of phospholipids. Phospholipase A1 is also 
specific for the sn-1 position but it has not been used much in phospholipid 
modifications. Phospholipase A2 has been used for the synthesis and modification of 
phospholipids through esterification (Hosokawa and others 1995) or acidolysis  
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Figure 2- Modification of phospholipids by combined use of lipases, phospholipase 
A2 (PLA2), and phospholipase D (PLD). (DArrigo and Servi 1997) 
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(Hosokawa and others 1998). A few reviews have also been published recently regarding 
the applications of phospholipases for phospholipid modification (Servi 1999; Ulbrich-
Hofmann 2000; Adlercreutz and others 2002). Lipases were used to modify the existing 
acyl chain of phospholipids (Yagi and others 1990; Mutua and Akoh 1993; Haraldsson 
and Thorarensen 1999; Svensson and others 1990). But lipases have found their most 
extensive use in fatty acid exchange at the sn-1 position of phospholipids (Adlercreutz 
and others 2002). Good selectivity for this position has been observed for several lipases, 
which are specific for the sn-1 and sn-3 positions of triacylglycerols (Yagi and others 
1990; Svensson and others 1990). Commercial availability of immobilized lipases makes 
the production of structured phospholipids with novel and/or defined fatty acids more 
feasible. Most studies have used organic solvents as reaction medium (Mustranta and 
others 1994a; Svensson and others 1990).  
Recently, Adlercreutz and others (2002) reviewed the use of lipases for fatty acid 
exchange in the sn-1 position and of phospholipases A2 for sn-2 position exchange. 
Modified tables obtained from that reviewer are shown in Table 1 and Table 2. Table 1 
shows the published results of lipase-catalyzed incorporation of fatty acids into the sn-1 
position of phospholipids and Table 2 shows that of phospholipase A2-catalyzed 
incorporation of fatty acids into the sn-2 position. To increase the incorporation of fatty 
acids into the phospholipids, combination of lipase and phospholipase has been used for 
phospholipid modification (Chamiel and others 1999; Aura and others 1995). 
Considerable efforts are being made to incorporate health promoting fatty acids into 
phospholipids. The primary targets of such efforts are medium chain fatty acids, n-3 
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polyunsaturated fatty acids, mainly eicopentaenoic acid (EPA), docosahexaenoic acid 
(DHA) and conjugated linoleic acid (CLA). Incorporation of DHA and EPA into 
Phospholipids was reported by several authors (Haraldsson and Thorarensen 1999; 
Mutua and Akoh 1993; Totani and Hara 1991; Na and others 1990). Reports on 
incorporation of medium chain fatty acids and CLA are limited. Recently, Peng and 
others (2002) reported the incorporation of caprylic (C8:0) and CLA into soybean 
phospholipids. Unlike all the above mentioned processes, where  substrate acyl chains  
were free fatty acids or fatty acid methyl esters form, recently Hara and others (2002) 
reported the enzymatic transesterification of phospholipids with monoacylglycerol (MG) 
or diacylglycerol (DG) having different acyl groups (C4-C18:3). 
 
 
 
Table 1- Example of lipase-catalyzed incorporation of new acids in phospholipids 
Entry 
No. 
Reaction type Lipase used Solvent Acid Incorp. 
(%) 
1 Acidolysis R. oryzae toluene C17:0 49.3 
2 Acidolysis R. miehei 
Lipozyme IM-60 
hexane C20:5 42 
3 Acidolysis R. miehei 
Lipozyme IM-60 
no C20:5 53 
4 Acidolysis R. miehei 
Lipozyme  TL IM 
no C8:0 38 
5 Esterification R. oryzae toluene C10:0 49.6 
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Table 2-Examples of phospholipase A2-catalyzed incorporation of new acids in the 
sn-2 position of phospholipids 
Entry 
No. 
Reaction type PLA2 used Solvent Acid Incorp. 
(%) 
1 Esterification pancreatic isooctane C22:6 35.0 
2 Esterification pancreatic glycerol C20:5 46.5 
3 Acidolysis pancreatic glycerol C20:5 36.0 
4 Acidolysis pancreatic toluene C6:0 41.0 
5 Esterification pancreatic toluene C6:0 50.0 
 
 
 
2.1.1.2 Polar head group modification of phospholipids 
 To produce structurally divergent phospholipids with different functional 
properties, several methods (physical, chemical, and enzymatic techniques) have been 
developed to modify the polar head group distribution of the native phospholipids (Doig 
and Diks 2003b). The polar head group of phospholipids can be best modified by using  
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enzymatic reactions catalyzed by phospholipase D (PLD). PLD catalyzes the hydrolysis 
of the terminal phosphodiester bond, yielding phosphatidic acid (PA), as well as the 
transphosphatidyl reaction (Frohman and Morris 1999). Phospholipase D from either 
cabbage or microbial sources such as Stretomyces sp. have been used to incorporate a 
wide range of novel head groups, including both primary and secondary alcohols into 
phosphatidylcholine (DArrigo and others 1996; Juneja and others 1987; Takami  and 
others 1994). Figure 3 shows the list of different head groups introduced by PLD into 
phospholipids (Ulbrich-Hofmann 2000). These reactions are usually carried out in 
aqueous/organic two-phase systems, where organic solvent is required to dissolve 
phospholipids and serve as substrate reservoir. The enzymes reside in the aqueous 
environment. But the biphasic reaction system results in the undesirable enzyme-
catalyzed hydrolysis of phospholipids (DArrigo and others 1996). So, a new reaction 
system suitable for phospholipase D-catalyzed transphosphatidylation of alcohols with 
phosphatidylcholine (PC) in anhydrous organic solvents was reported (Rich and 
Khmelnitsky 2001).  
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Figure 3-Head group introduced by phospholipase D into glycerophospholipids. 
(Ulbrich-Hofmann 2000) 
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2.1.2 Phospholipids for nutraceuticals and functional foods 
 Phospholipids exhibit a wide range of nutritional and even preventive or 
therapeutic activities (Schneider 2001). Kidd (2002) also reported phospholipids as 
versatile nutraceutical ingredients for functional foods and reviewed their clinical 
efficacy and safety. Mastellone and others (2000) clearly established the beneficial 
metabolic effects of dietary soybean lecithin on lipid metabolism. The intestinal 
absorption of cholesterol was decreased by soybean phosphatidylcholine-enriched diet 
and resulted in a cholesterol-lowering effect. In another report, soy phosphatidylcholine 
showed beneficial effect on liver detoxification and repair of damaged liver tissue 
(Leiber and others 1990) Phosphatidylcholine and other egg phospholipids added to 
infant formula markedly reduced life-threatening necrotizing enterocolitis in hospitalized 
preterm babies (Carlson and others 1998). The efficacy of phosphatidylserine (PS) for 
cognition and other higher brain functions was established (Pepeu and others 1996, 
Jorissen and others 2001). Because of the natural tendency of phospholipids to form 
ultra fine molecular dispersions, they can be used to improve the bioavailability of 
lipophilic nutrients. The right type of phospholipids combined with the active substance 
enhanced their bioavailability dramatically (Leigh and Leigh 1999). 
 
2.1.3 Therapeutic phospholipids 
Phospholipids combined with certain nutrients through modification of natural 
phospholipids have further health benefits. Polyunsaturated fatty acids, mainly n-3 fatty 
acids-containing phospholipids are currently receiving attention because of their novel 
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physiological functions. Hosokawa and others (1995) reported weight decrease in some 
major organ adipose tissue after the administration of eicosapentaenoic acid (EPA 
C20:5) containing phospholipids. Hosokawa and others (1995) mentioned that 
docosahexaenoic acid (DHA C22:6) containing phosphatidylcholine (DHA-PC) induced 
differentiation of murine tumor cells. Polyunsaturated fatty acid containing 
phospholipids (PUFA-PL) produced by enterobacteria in certain fishes reduce levels of 
neutral fat or cholesterol (Totani and Hara 1991). Phosphatidylcholine (PC) with 
eicosapentaenoic (EPA C20:5) and docosahexaenoic acid (DHA C22:6) at the sn-2 
position could be digested more easily in the body and might be of value in nutritional 
and medical applications. 
 
2.2 Conjugated linoleic acid 
 Conjugated linoleic acid, commonly known as CLA, is mixture of positional (C8, 
C10; C9, C11; C10, C12; and C11, C13) and geometric (cis, cis; cis, trans; trans, cis; 
and trans, trans) isomers of linoleic acid (C18:2 n-6) (Ha and others 1987). In the native 
food system CLA is mainly formed during the biohydrogenation of linoleates by rumen 
bacteria. So, food products derived from ruminants are the major sources of CLA. 
Virtually all cis- and trans- isomeric combinations of CLA have been identified in food. 
However, the cis-9, trans-11 isomer of CLA is predominant in natural food systems 
(McGuire and others 1999). In milk fat, this isomer is about 85% of total CLA isomers 
(Chin and others; Shanta and others 1995). The cis-9, trans-11 isomer and trans-10, cis-
12 isomer of CLA (Figure 4) are considered to be the major biologically active isomers 
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(Gnädig and others 2001). Reaney and others 2002 described research on CLA between 
1935 and 2002 relating to its discovery, synthesis, and analysis. 
 
 
 
 
Figure 4- Structures of two major biologically active CLA isomers and linoleic acid 
(C18:2 n-6). (Pariza 2004) 
 
 
 
 
 
t10, c12 CLA 
c9, t11 CLA 
Linoleic acid 
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2.2.1 Sources of CLA 
 As stated before, ruminant species and their products are rich dietary sources of 
CLA. Vegetable oils are poor sources of CLA; however, safflower and sunflower oils 
have 0.7 and 0.4 mg CLA/g of fat respectively (Table 3, Rainer and Heiss 2004). CLA 
concentrations in dairy products typically range from 2.9 to 8.92 mg / g fat. CLA content 
of cheeses typically ranges from 3.59 to 7.96 mg/g fat (McDonald 2000). Cultured dairy 
products usually have 3.82 to 4.66 mg CLA/g fat (Lin and others 1995).  
 
 
 
Table 3- Conjugated linoleic acid content of various foods 
Food mg/g fat Food mg/g fat 
    
Dairy Products  Meats/Fish  
Homogenized milk 5.5 Fresh ground beef 4.3 
2% milk 4.1 Veal 2.7 
Butter fat 6.1 Lamb 5.8 
Condensed milk 7.0 Pork 0.6 
Cultured buttermilk 5.4 Chicken 0.9 
Butter 4.7 Fresh ground turkey 2.6 
Sour cream 4.6 Salmon 0.3 
Ice cream 3.6 Egg yolk 0.6 
Low-fat yogurt 4.4   
Custard style yogurt 4.8 Vegetable Oils  
Plain yogurt 4.8 Safflower oil 0.7 
Frozen yogurt 2.8 Sunflower oil 0.4 
Medium chedder 4.1   
American processed 5.0   
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Variation of CLA content in foods is affected by the ruminants diet (type of 
feed, feeding regimen, grass quantity, dietary restriction), ruminant age or breed, and 
seasonal factors (OShea and others 1998). Cows from Australia and New Zealand have 
2-3 times higher CLA concentrations than cows in North America and Northern Europe 
(OShea and others 1998). CLA isomers can also be commercially produced by alkali 
isomerization or by partial hydrogenation of linoleic acid (Banni 2002). Production of 
free CLA by lactic acid bacteria Lactoacillus acidophilus and Lactobacillus casei in 
medium supplemented with linoleic acid was reported by Alonso and others (2003). 
 
2.2.2 Health properties of CLA 
 Numerous physiological properties have been attributed to CLA mostly in 
experimental animal models including antiadipogenic, antidiabetogenic, 
anticarcinogenic, and antiatherosclerotic activities. In addition, CLA affects on bone 
formation, immune system, lipid metabolism, and gene expression in numerous tissues. 
Some of these physiological properties and their effects on the models are summarized 
in Table 4 (Belury 2002). 
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Table 4- Physiological properties of conjugated linoleic acid 
Major Function Physiological Model 
Body ↓ Adiposity in chicks, mice, and rats 
 ↑ Adiposity in obese Zucker rats; ↓ Adiposity in ZDF 
 ↓ Adiposity is isomer specific (trans-10, cis-12 CLA) 
 ↓ Adiposity in human subjects; ↔ Adiposity in human 
Diabetes ↓Onset of diabetes in ZDF male rats 
 Aids in the management of metabolic parameters in 
 subjects with type 2 diabetes 
 ↓ Insulin sensitivity in mice 
Carcinogenesis ↓ Chemically induced mammary carcinogenesis in rats 
 ↓ Chemically induced mammary carcinogenesis in rats 
    cis-9, trans-11 CLA or synthetic CLA 
 ↓ Chemically induced mammary carcinogenesis in rats 
    of level of fat or esterification of CLA (in triglyceride) 
 ↓ Growth of transplantable breast cancer tumor cells in 
 ↓ Growth of transplantable prostate cancer tumor cells in 
 ↓ Stages of chemically induced skin tumorigenesis in 
 ↓ Chemically induced colon carcinogenesis in rats 
 ↔ Carcinogenesis in Min mice 
 ↓ Chemically induced forestomach 
Atherosclerosis ↓ Atherosclerotic plaque formation in hamsters 
Bone formation ↓ Eicosanoid production 
Immune system ↓ Eicosanoid and histamine production 
 ↑ Onset of lupus in mouse model 
↓, decrease; ↑, increase; ↔, no effect; ZDF, Zucker diabetic fatty. 
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2.2.2.1 Anticarcinogenic properties of CLA 
Anticarcinogenic effect of CLA was first observed by Pariza and Hargraves 
(1985) in cooked beef. They established that anticarcinogenic effect was associated with 
conjugated dienoic isomers of linoleic acid, termed CLA. In the 1990s, several other 
studies reported anticarcinogenic activity of CLA against chemical carcinogens (Ip and 
others 1991; Ip and others 1994). CLA also displayed anticarcinogenic effects against 
breast, colon, and prostrate cancer cell lines (Cesano and others 1998; Park and others 
2001). But, not all studies consistently demonstrated that CLA inhibited carcinogenesis. 
CLA was unable to alter the growth of transplanted prostate (Scimeca 1999) and breast 
(Wong and others 1997) cancer cells and did not reduce tumorigenesis in an intestinal 
model of colon carcinogenesis using specific mouse model (Petrick and others 2000). A 
number of processes are thought to be responsible for mediating anticancer effects of 
CLA. Park and others (2001) reported that CLA may reduce incidence of cancer by 
increasing apoptotic cell death of cancer cells. A study with CD2F1Cr mice showed the 
isomer specific adipose apoptotic effect. The trans-10, cis-12 isomer, not cis-9, trans-11 
isomer of CLA rapidly induced apoptosis of the white and brown adipocytes (Masso-
Welch and others 2004). Park and others (2001) reported that dietary CLA inhibited 1,2-
dimethylhydrazine-induced colon carcinogenesis by mechanisms probably involving 
increased apoptosis. Studies involving the evaluation of anticarcinogenic effect of CLA 
in humans have shown limited evidence for a direct association between CLA intake and 
cancer reduction in humans. However, a recent case-control study in Finnish women 
suggested that dietary CLA may be protective against breast cancer (Aro and others 
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2000). In their review article, Ip and others (2003) suggested that CLA may be an 
excellent candidate for prevention of breast cancer. Thus, the role of CLA in prevention 
or treatment of cancer in humans requires more research. 
 
2.2.2.2 Antiatherosclerotic effects of CLA 
Antiatherosclerotic effects of CLA have been reported in experiments with 
hamsters and rabbits fed high-cholesterol diets, as measured by improved blood lipid 
profiles (Lee and others 1998; Nicolosi and others 1997). CLA also causes regression of 
established atherosclerosis in rabbits (Kritchevsky and others 2000). Truitt and others 
reported the inhibitory effects of platelet aggregation by mixtures and individual isomers 
of trans-10, cis-12 CLA and cis-9, trans-11 CLA. However, CLA does not appear to 
produce identical results in all animal models of atherosclerosis. Diets with 1% CLA 
resulted in increasing levels of triglycerides, VLDL, and LDL cholesterol in adult female 
pigs (Stangl and others 1999). 
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2.2.2.3 Conjugated linoleic acid reduces adipose tissue 
Wang and Jones (2004) reviewed numerous studies in various animals and cell 
cultures that demonstrated the ability of CLA to reduce fat tissue deposition as well as 
cellular and whole-body lipid content. The inhibitory effect of CLA on adiposity was 
likely due to trans-10, cis-12 isomer of CLA (Park and others 1999; Ostrowska and 
others 1999). CLA accelerates the decomposition of storage lipids in white adipose 
tissue (WAT) and clearance of serum nonesterified fatty acid (NEFA) levels, resulting in 
lipid peroxidation and a morphological change in the rat liver (Yamasaki and others 
2000). Unlike growing rats, adult male rats did not respond to the fat-to-lean partitioning 
effect of CLA (Mirand and others 2004). In humans, although it is indicated that trans-
10, cis-12 isomer of CLA is the antiadipogenic isomer (Blankson and others 2000; Thom 
and others 2001), the effects of CLA on fat deposition are less significant as compared to 
results observed in animals. Possible mechanisms through which dietary CLA reduce 
body fat deposition has been summarized in Figure 5. 
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Figure 5-Possible mechanisms of antiadiposity action of conjugated linoleic acid. 
⊕, enhance; ∅, suppress. (Wang and Jones 2004) 
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2.2.2.4 Antidiabetogenic properties of CLA 
Houseknecht and others (1998) reported that CLA can improve blood glucose 
control and prevent the development of elevated blood sugar levels in diabetic animal 
models by acting as an insulin-sensitizer. In another study with Zucker diabetic fatty 
fa/fa rat, dietary CLA restored insulin sensitivity what led to the proposal that CLA 
might be useful in treating type-2 diabetes (Belury and Vanden 1999). Recently, it was 
noticed that diabetic rats fed either a 50:50 mixture of trans-10, cis-12 CLA and cis-9, 
trans-11 CLA isomers or a 90% cis-9, trans-11 CLA isomer experienced stimulated 
insulin action in fat and muscle cells (Ryder and others 2001). The findings suggest that 
CLA can prevent and/or delay the onset of diabetes and that the cis-9, trans-11 isomer 
may contribute much of this activity.  
 
2.2.2.5 Conjugated linoleic acid modulates lipid metabolism 
Various studies have shown that CLA affects lipid metabolism. A comprehensive 
review by Belury (2002) reported that dietary CLA alters the levels of other fatty acids 
in phospholipids and neutral lipids in the liver. Park and others (2000) observed the 
decrease in palmitoleic and oleic acids in hepatic neural lipids by trans-10, cis-12 CLA 
isomer in mice. Banni and others (2001) also mentioned that it is possible that the altered 
levels of monounsaturated fatty acids such as palmitoleate and oleate may result from 
displacement of monounsaturated fatty acids by CLA. In addition, CLA may alter 
enzymatic pathways responsible for altering fatty acid composition of lipid fractions. In 
fact, CLA has been shown to reduce the ∆9 desaturase in mouse liver (Lee and others 
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1998). Supplementation of CLA in the diet of laying hens decreased the concentration of 
oleic acid (18:1 n-9), arachidonic acid (20:4 n-6), and docosahexaenoic acid (22:6 n-3) 
but increased that of linolenic acid (18:3 n-3), stearic acid (18:0), and palmitic acid 
(16:0) in the egg yolk, suggesting that CLA may inhibit ∆6 and ∆9 desaturases (Yang 
and others 2002). In another study, exogenous conjugated linoleic isomers reduced 
bovine milk fat concentration and yield by inhibiting De Novo fatty acid synthesis (Loor 
and Herbein 1998).The schematic pathway how CLA modulates metabolism of 
nonconjugated fatty acids via enzymatic systems such as ∆6 desaturase-elongase-∆5 
desaturase and alters eicosanoid formation is shown in Figure 6. A recent study showed 
that the cis-9, trans-11 CLA isomer inhibited arachidonic acid conversion to prostaglin 
E2 by 20-30% in human breast cancer cell line (Miller and others 2001). In addition, 
CLA was shown to inhibit the activity of ∆6 desaturase, a rate limiting enzyme for the 
conversion of eicosanoid precursors (Chuang and others 2001). In particular, Belury 
(2002) proposed that CLA modulates lipid metabolism, in part, by a mechanism 
dependent on the activation of the group of nuclear transcription factors, peroxisome 
proliferators-activated receptors (PPARs). 
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Figure 6- Pathway for desaturation and elongation of CLA and schematic pathway 
for eicosanoid synthesis from arachidonate. 
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2.2.2.6 CLA effects on immune system 
 Hayek and others (1999) reported that dietary CLA influenced immune response 
in mice. In an earlier study, Cook and others (1993) found that CLA-fed rats exhibited 
enhanced immune function. CLA administration enhanced cellular immunity in pigs by 
modulating white blood cell types that control adaptive and innate immunity 
(Bassaganya-Riera and others 2001). According to Pariza (1999), CLA is the only 
known dietary factor that both enhances the immune system and at the same time 
protects against the catabolic effects of immune stimulation, suggesting potential further 
applications of CLA to the improvement of health. However, no effects were observed 
on several measures of immune function including delayed-type hypersensitivity 
response, number of circulating white blood cells, and antibodies to vaccine following 
the feeding of CLA to young healthy women (Kelley and others 2000). Difference in 
immune responses may be due to the selection of a young, healthy population with 
optimal immune function, species difference, or dietary CLA isomer composition 
(Kapoor and others 2003). 
 
2.3 CLA in human studies 
 Numerous scientific reviews on biological effects of CLA in animal models and 
cell culture experiments indicated that CLA could be useful in improving human health. 
More research is required in humans to confirm these beneficial effects before CLA 
supplementation can be used as nutraceutical or chronic disease prevention. Several 
studies were reported with human subjects. A study with 60 overweight men and women 
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showed that consumption of 1.8 or 3.6 gm CLA/day for 13-week affected the regain of 
fat-free mass dose independently and increased the resting metabolic rate without 
improving the body weight maintenance after weight loss (Kamphuis and others 2003a).  
In another study, Kamphuis and others (2003b) observed that 13-week supplementation 
with CLA in 60 overweight subjects after body weight loss did not affect body-weight 
maintenance, but favorably affected the subjective parameters of appetite (satiety, 
fullness, hunger). A study by Noone and others (2002) confirmed that some of the 
cardio-protective effects of CLA that were shown in animal studies are relevant to men. 
They observed that 50:50 CLA isomer blend (cis-9, trans-11, trans-10, cis-12) 
significantly reduced fasting plasma TAG concentration in human subjects whereas 
80:20 CLA isomer blend significantly reduced VLDL-cholesterol concentration. CLA 
supplementation had no significant effect on LDL-cholesterol, HDL-lipid-protein 
composition or reverse cholesterol transport. CLA supplementation for 4 weeks in 
twenty-five obese men with metabolic syndrome decreased abdominal fat without 
concomitant effects on overall obesity or other cardiovascular risk factors (Risérus and 
others 2001). Another study indicated that supplementation with 2.1 g of CLA daily for 
45 days increased CLA concentration in blood but had no effect on body composition or 
lipid profile of non obese women (Petridou and others 2003). Brown and Mclntosh 
(2003) reviewed CLA isomer-specific regulation of adiposity and insulin sensitivity in 
humans. A recent study with 6 healthy women showed no effect of dietary CLA on FA 
metabolism. But CLA positional isomers were metabolically different and conversion of 
CLA isomers to desaturated and elongated metabolites was low (Emken and others 
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2002). Recently, Risérus and others (2003) reported that CLA may slightly decrease 
abdominal fat without simultaneous reduction of body weight or improvement of lipid or 
glucose metabolism. Rather, they indicated that the trans-10, cis-12 isomer unexpectedly 
caused significant impairment of peripheral insulin sensitivity as well as blood glucose 
and serum lipid levels. In addition, CLA markedly elevated lipid peroxidation. Albers 
and others (2003) suggested that CLA may beneficially affect the initiation of a specific 
response to a hepatitis B vaccination. They observed that 60% subjects who consumed 
50:50 (cis-9, trans-11 and trans-10, cis-12) CLA isomers had protective antibody levels 
to hepatitis B compared to 33% subjects who had reference diet and 36% subjects who 
consumed 80:20 CLA isomers. Most of the studies stated above used CLA mixtures 
containing two major isomers. A recent study by Risérus and others (2000) with pure 
trans-10, cis-12 CLA isomer revealed unexpected metabolic actions by this isomer in 
humans. This trans-10, cis-12 CLA isomer, but not a CLA mixture (with isomers cis-9, 
trans-11 and trans-10, cis-12), significantly increased insulin resistance, fasting glucose, 
and dyslipidemia in abdominally obese men. Recently, Risérus and others (2004) 
suggested that human supplementation with high doses of the trans-10, cis-12 CLA 
isomer should be avoided while awaiting further information on possible effects and side 
effects.  
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2.4 Safety aspects of conjugated linoleic acid 
 Regarding a possible application of CLA in functional food, it is important to 
know about possible toxicological activities of CLA. Until today, only few studies 
investigated toxicological aspects of CLA supplementation. Scimeca (1998) conducted a 
36-week rat feeding trial with 1.5% CLA supplemented diet, a level about 30% greater 
than humans would ingest at 3g CLA/day. Food disappearance, body weights, cage side 
examinations, and hematologic and histopathologic analysis of 15 major organs were 
conducted. No adverse effects were observed. Recently, a 5-month mice feeding study 
with CLA observed a reduction of white adipose tissue, while tumor necrosis factor α 
increased 12-fold and (UCP)-2 mRNA-levels were up regulated 6-fold. The author 
mentioned that CLA supplementation resulted in something similar to lipoathrophic 
diabetes (Tsuboyama-kasaoka and others 2000). A human double-blind placebo-
controlled study was carried out on overweight volunteers to test the safety of CLA 
supplementation and effect on body composition was investigated (Berven and others 
2000). No differences between the CLA-supplemented and the control group were found 
on blood parameters such as blood lipids, hematology, liver enzymes, blood electrolytes, 
creatinine and lactate dehydrogenase or clinical vital signs, such as blood pressure or 
heart rate. A number of other human clinical trials also reported that high-quality CLA, 
when consumed at 3-6 g/d, did not appear to induce adverse effects in humans (Noone 
and others 2002, Albers and others 2003; Kamphuis and others 2003a). Despite these 
studies, some researchers have recently raised concerns about the potential safety of 
CLA for humans (Larsen and others 2003; Risérus and others 2004). The reported 
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concerns are the induction of fatty liver, insulin resistance, and lipodystrophy in mice fed 
CLA supplemented diets and enhanced C-reactive protein, lipid peroxidation, 
unfavorable changes in serum lipids, and reduced milk fat in human trials. Recently, 
Pariza (2004) discussed all these concerns considering overall scientific literature 
database on CLA. So, more research is needed to confirm the safety of CLA isomers 
individually or collectively.  
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CHAPTER III 
 
 
MATERIALS AND METHODS: SYNTHESIS OF STRUCTURED  
PHOSPHOLIPIDS WITH CLA  
 
 
 
3.1 Materials 
 
 Soybean phospholipids, Lipoid S100 (phosphatidylcholine ≈ 94%) and Lipoid 
S20 (phospatidylcholine 20-24%) and egg yolk phospholipids, Lipoid E PC S 
(phophatidylcholine ≈ 98%) and Lipoid E 80 (phosphatidylcholine ≈ 80%) were 
provided by Lipoid GmBH (Ludwigshafen, Germany). Phospholipid from fresh egg yolk 
was isolated according to the procedure descried by Singleton and others (1965). 
Safflower oil used for the synthesis of CLA was purchased from a local super market. 
3.1.1 Enzymes 
Immobilized lipases from Mucor miechei (Lipozyme RM IM), Thermomyces 
lanuginose (Lipozyme TL IM) and Candida Antarctica (Novozym 435), and 
phospholipase A2 from Porcine pancreas (Lecitase 10 L) were donated by Novozym es 
North America (Franklinton, NC). Lipase from Rhizopus oryzae (Lipase F-AP15) in 
powder form was provided by Amano Enzyme USA Co. Ltd. (Elgin, IL). 
3.1.2 Chemicals 
Soybean and egg yolk phosphatidylcholine (99% purity), other individual 
phospholipid standards , a mixture of 37 fatty acid methyl esters to identify the different 
fatty acids , and other chemicals and reagents were purchased from Sigma Chemical 
Company (St. Louis, MO). CLA reference standards (+98% pure) of cis-9, trans-11, and 
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trans-10, cis-12 CLA and 1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine (DPPC, MW 
734.1) obtained from Matreya, Inc. (PA, USA). All solvents used were of HPLC grade 
and purchased from VWR-Scientific Products (McGaw Park, IL). 
 
3.2 Methods 
3.2.1 Synthesis of CLA 
CLA as free fatty acids were produced by alkali isomerization of safflower oil 
with7% NaOH in propylene glycol at 180oC for 2h according to Rocha-Uribe and 
Hernandez (2004). Propylene glycol was used to produce high yields of the two major 
active isomers (i.e. cis-9, trans-11, and trans-10, cis-12 CLA isomers). 500g of 
safflower oil was added to a 5-liter, 3-neck flask containing 218g of NaOH dissolved in 
2900 g of propylene glycol. The flask was equipped with a mechanical stirrer, a 
thermometer, a reflux condenser and a nitrogen (N2) inlet. The mixture was flushed with 
N2 and heated to180oC for 2h. The resulting isomerized mixtures (CLA-containing 
mixtures) were collected after neutralizing with HCl followed by hexane extraction and 
water washing according to Rocha-Uribe (2002). 
 
3.2.2 Enzyme catalyzed acidolysis reaction 
 Deoiled phospholipids from different sources (soybean, egg yolk) with different 
phosphatidylcholine (PC) content and isomerized CLA mixture were interesterified by 
different lipases, by phospholipase A2, and by combination of one the four lipases and 
phospholipase A2 according to the reaction scheme 1 (Figure 7).  
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Figure 7- Reaction scheme 1 of lipase and phospholipase mediated acidolysis 
reaction. R1 and R2 are natural alkyl groups.  
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3.2.2.1 Lipase catalyzed acidolysis reaction 
 
 In a typical reaction, 100 mg of phospholipid was mixed with 185 mg of 
isomerized CLA mixtures (1:5 mol phospholipids/mol CLA) in 1 ml of hexane in screw 
cap vial. 20% of lipase enzyme (wt.% of phospholipids) was added to the reaction 
mixture. About 2 µl of water was sprayed to the immobilized lipases only and 
conditioned at 4oC before adding to the reaction mixture. The reaction was carried out at 
40oC for enzymes Lipozyme RM IM and Lipase F-AP15. When enzymes Novozym 435 
and Lipozyme TL IM were used, the reaction was carried out at 57oC. The reaction was 
started in a water bath with magnetic stirring at 300 rpm. From the reaction mixture,    
50 µl of aliquot was collected in vials over different time intervals. The solvent was 
evaporated by N2 blowing and 300 µl of chloroform: methanol (2:1) was added into the 
residue and centrifuged for 5 min using a mini-centrifuge (Phenix Rsearch System, 
Hayward, CA). The solvent layer was carefully withdrawn and kept in the freezer        
(<-20oC) for analysis. 
 
3.2.2.2 Phospholipase A2 (PLA2) catalyzed acidolysis reaction 
 The acidolysis reaction between phospholipids and CLA mixtures was also 
carried out by PLA2 (Lecitase 10L) after immobilization. The Lecitase 10L was 
immobilized on diatomaceous earth (Celite) by adsorption according to the procedure 
described by Aura and others (1995). In the reaction catalyzed by immobilized PLA2, 20 
mg of immobilized enzyme was added into the reaction mixture of 100 mg 
phospholipids and 185 mg CLA mixtures dissolved in 1 ml of hexane. 8µl of Tris-HCL 
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buffer (pH 8) containing 20 mM CaCl2 was sprayed over immobilized PLA2 before 
adding into the reaction mixture. The reaction was carried out at 50oC in a screw cap vial 
placed in a water bath with magnetic stirring at 300 rpm. The samples were collected for 
analysis as mentioned earlier. 
 
3.2.2.3 Lipase and phospholipase A2 catalyzed acidolysis reaction 
 In this reaction, both enzymes lipase and phospholipase A2 were used together. 
In a typical reaction, 100 mg of phospholipid was mixed with 185 mg of isomerized 
CLA mixtures in 1 ml of hexane. 20 mg of lipase from either Lipozyme RM IM or 
Lipozyme TL IM along with 10 mg of immobilized Lecitase 10L was added into the 
reaction mixture. No buffer was added but 2µl of water was sprayed over lipase enzymes 
before they were added into the reaction mixture. The temperatures of the reaction were 
40oC and 57oC when Lipozyme RM IM and Lipozyme TL IM were used respectively. 
 
3.2.3 Phospholipids analysis by TLC and HPLC 
 TLC analysis. TLC was used to monitor the acidolysis reaction and isolate the 
reaction products. Aliquots collected in chloroform: methanol (described above) at 
different time intervals were applied to TLC plates (silica gel 60 F254, E. Merck Co., 
Darmstadt, Germany). The plates were developed with chloroform/methanol/water 
(65:25:4 by vol.). Eluted compounds were detected by spraying 5% phosphomolybdic 
acid in ethanol followed by heating.  
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 HPLC analysis. To measure the degree of hydrolysis of phospholipids during 
acidolysis reaction, a Beckman System Gold Module HPLC System (Beckman 
Instrument Inc., Fullerton, CA) with 508 auto sampler module (20µl injection loop) , 126 
pump module and 168 detector module was used. A normal-phase silica column 
(Lichrosorb , Phenomenex) was used at room temperature for this analysis. The mobile 
phase was acetonitrile/methanol/phosphoric acid (130:5:1.5, vol/vol) run isocratically, 
and flow rate was 1.5 ml/min. The component phospholipids were detected at 205 nm.  
 
3.2.4 Fatty acid analysis of structured phospholipids 
 Fatty acid composition of phospholipids classes in acidolysis reaction was 
determined by using preparative TLC followed by gas chromatographic (GC) analysis. 
Reaction products were first separated on preparative TLC plates (10cm × 10cm) by 
developing with mobile phase chloroform/methanol/water (65:25:4 by vol.). Part of the 
plate was carefully cut and eluted compounds were detected by spraying 5% 
phosphomolybdic acid in ethanol followed by heating. This was used as template to 
identify the phospholipids classes which were then scraped off from the TLC plates and 
put into a test tube for fatty acid methyl ester preparation of individual class. Fatty acid 
methyl esters were prepared by adding 1.0 ml of 0.25 M sodium methoxide in 
methanol/diethylether (1:1) to the scrapings in test tubes from the TLC plates. After 
incubation for 5 min in a water bath shaker at 45oC, 500 µl of hexane was added 
followed by 3 ml of saturated NaCl solution. After vortexing and centrifugation, another 
500µl of hexane was added and methyl esters extracted in hexane were collected from 
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upper layer for GC analysis. A Varian Model 3400 GC system equipped with a split 
injector, a flame ionization detector, and a fused silica capillary column Supelco SP 
2560 (100 m, 0.25 mm I.D., 0.20 µm film, Bellefonte, PA) was used for fatty acid 
methyl esters analysis. The initial column oven temperature was 150oC for 3 min and 
then raised to 200oC at 10oC/min, finally it was raised to 230oC at rate 3oC/min and held 
for 10 min. The injector and detector temperatures were 250oC and 300oC respectively. 
The hydrogen was used as carrier gas. Fatty acids were identified by comparing their 
retention times with those of standards. 
 
3.2.5 Optimization of acidolysis reaction 
 Experimental design. A three-level four-factor Central Composite Rotatable 
Design (CCRD) was used according to the principle of Response Surface Methodology 
(RSM) to optimize the acidolysis reaction conditions for maximum incorporation of 
CLA into phospholipids. The four factors chosen as independent variables were, enzyme 
load (Ed, wt.% of phospholipids), substrate ratio (Sr, CLA/PL, mol/mol), temperature (Te, 
oC), and reaction time (ti, h). The incorporation of CLA into phospholipids was the 
response. The ranges of the four factors (Ed, 15-25%, Sr, 3.5-6.5%, Te, 50-60 oC, ti, 30-70 
h) were chosen based on the primary experiments with single factor and variable ranges 
published in the literature (Peng and others 2002). The variables with actual and coded 
ranges are presented in Table 5. 
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Table 5- Experimental setting of three-level, four factor response surface design for 
optimization of incorporation of CLA into phospholipids 
Variable (coded) Variable (actual) Experiment 
Ed Sr Te ti Ed Sr Te ti 
1 -1 -1 -1 -1 15 3.5 50 30 
2  1 -1 -1 -1 25 3.5 50 30 
3 -1  1 -1 -1 15 6.5 50 30 
4  1  1 -1 -1 25 6.5 50 30 
5 -1 -1  1 -1 15 3.5 60 30 
6  1 -1  1 -1 25 3.5 60 30 
7 -1  1  1 -1 15 6.5 60 30 
8  1  1  1 -1 25 6.5 60 30 
9 -1 -1 -1  1 15 3.5 50 70 
10  1 -1 -1  1 25 3.5 50 70 
11 -1 1 -1  1 15 6.5 50 70 
12  1  1 -1  1 25 6.5 50 70 
13 -1 -1  1  1 15 3.5 60 70 
14  1 -1  1  1 25 3.5 60 70 
15 -1  1  1  1 15 6.5 60 70 
16  1  1  1  1 25 6.5 60 70 
17 -2  0  0  0 10 5.0 55 50 
18  2  0  0  0 30 5.0 55 50 
19  0 -2  0  0 20 2.0 55 50 
20  0  2  0  0 20 8.0 55 50 
21  0  0 -2  0 20 5.0 45 50 
22  0  0  2  0 20 5.0 65 50 
23  0  0  0 -2 20 5.0 55 10 
24  0  0  0  2 20 5.0 55 90 
25  0  0  0  0 20 5.0 55 50 
26  0  0  0  0 20 5.0 55 50 
27  0  0  0  0 20 5.0 55 50 
28  0  0  0  0 20 5.0 55 50 
Abbreviations: Ed, lipase dosage (wt.% of phospholipids); Sr, substrate ratio (CLA/PL, 
mol/mol); Te, reaction temperature (oC); ti, reaction time (h). 
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Statistical design. The data were analyzed using the response surface regression 
(RSREG) procedure of SAS statistical software (SAS Institute). The incorporation of 
conjugated linoleic acid (CLA), which is the most important factor, was used as main 
responses for the model evaluation. The degree of hydrolysis of phospholipids was also 
fitted into the model for evaluation. Response was first fitted to the factors by multiple 
regression, and then the models generated were used to evaluate the effects of various 
factors. The goodness of fit was evaluated by the coefficients of determination (R2) and 
the analysis of variances (ANOVA). The first- or second- order coefficients were 
generated by regression analysis with backward elimination method. The insignificant 
coefficients were eliminated after evaluating the coefficients and the model was refined. 
The quadratic response surface model was fitted to the following equation: 
            Y = βo + ∑ βixi + ∑ βii xi2 + ∑ ∑ βijxixj                                          (1) 
where Y is the response variable, βo is the intercept, βi is the first-order model 
coefficient, βii is the quadratic coefficient for the ith variable, βij is the interaction 
coefficient for the interaction of variables i and j, and xi and xj are ith and jth independent 
variables respectively. Response surfaces were developed using the fitted quadratic 
polynomial equations obtained from RSREG analysis and holding the independent 
variables with the least effect on the response at a constant value and changing the levels 
of the other two variables. 
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3.2.6 Stability of CLA-PL containing emulsions 
 Whey protein (1%) based oil-in-water emulsions with 10% oil (commercial 
soybean oil) and 0.5% phospholipids were prepared according to the method of 
Hernandez (2001). Samples were homogenized at 20 MPa using an APV Rannie Lab 
2000 Homogenizer (Albertslund, Denmark). Particle size distribution was measured by 
Coulter LS 130 light scattering apparatus (Coulter Corporation, Miami, FL) after 
diluting the samples with water and using real refractive index of 1.33 for water. 
Peroxide value and p-anisidine value of oil extracted from emulsions were measured by 
AOCS official methods - Cd 8-53 and Cd 18-90 respectively. Oil was extracted from 
emulsions according to Osborn-Barnes and Akoh (2003). 
 
3.2.7 Physiological study of CLA containing structured phospholipids 
 This study was done in collaboration with the Department of Nutrition and Food 
Science, Texas Woman University, Denton, TX. The impact of the structured 
phospholipids with CLA on the proliferation of tumor and colon cancer cells was 
evaluated. The cultures, seeded with 3.3 × 104 cells/ml were first incubated and then the 
samples dissolved in ethanol were added and incubated for 72 h according to the 
procedure of McAnally and others (2003). The viable cells were harvested, counted and 
expressed as % of control growth. 
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CHAPTER IV 
 
 
RESULTS, DISCUSSIONS, AND SUMMARY: 
SYNTHESIS OF STRUCTURED PHOSPHOLIPIDS WITH CLA 
 
 
 
4.1 Synthesis of CLA 
  
 The fatty acid composition of starting safflower oil and that of alkali isomerized 
CLA mixture is shown in Table 6. Mainly the linoleic acid was converted to conjugated 
linoleic acid (CLA). About 97.7% of linoleic acid of safflower oil was converted to 
CLA. The two major isomers cis-9, trans-11 and trans-10, cis-12 of CLA were well 
resolved during fatty acid profile analysis by our gas chromatographic (GC) system with 
100 m capillary column. These two major isomers are 97.4% of total isomers 
synthesized by alkali isomerization and are approximately equal in amount, 48.2% of 
cis-9, trans-11 isomer and 49.2% of trans-10, cis-12 isomer. The composition of other 
fatty acids (palmitic, C16; stearic, C18:0; oleic, C18:1) present in starting safflower oil 
was similar after alkali isomerization.  
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Table 6. Fatty acid composition of safflower oil before and after alkali 
isomerization 
 Fatty acid composition (% area) 
Fatty acid Safflower oila Isomerized mixtureb 
C16:0 6.7 ± 0.14 6.7 ± 0.32 
C18:0 2.6 ± 0.18 2.6 ± 0.22 
C18:1 15.4 ± 0.54 15.4 ± 0.61 
C18:2 74.5 ± 1.3 1.7 ± 0.11 
CLAc  72.8 ± 2.1 
cis-9 , trans-11- CLA  35.1 ± 1.1 
trans-10, cis-12- CLA  35.8 ± 1.3 
Others 0.7 ± 0.03 2.6 ± 0.04 
a Starting safflower oil. Mean ± standard deviation of three analyses. 
b Fatty acids after alkali isomerization. Mean ± standard deviation of three analyses. 
c Total conjugated linoleic acid isomers. 
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4.2 Enzyme catalyzed CLA incorporation in phospholipids 
 
 Enzyme catalyzed acidolysis reaction between phospholipids and free fatty acids 
is an effective way to modify phospholipids with exchanged acyl chains for specific 
needs. In this study we tried to incorporate CLA into phospholipids. In the series of 
experiments with four different lipases and one phospholipase A2, we found that rate of 
incorporation of CLA depends on enzyme or combination of enzymes used. 
 
4.2.1 Lipase catalyzed acidolysis reaction 
Triacylglycerols are known substrate for lipase enzymes. Like many other reports 
mentioned in chapter II, our results also showed that lipases have phospholipase 
(phospholipids are known substrate) activity as well. Among the four different lipases 
(Lipozyme RM IM, Lipozyme TL IM, Novozym 435, and Lipase F-AP15) used, only 
Lipozyme RM IM and Lipozyme TL IM were effective in incorporation of two major 
CLA isomers into phospholipids (Tables 7 through 10). The two major ismomers- cis-9, 
trans-11 and trans-10, cis-12 of CLA were equally incorporated into the soybean 
phosphatidylcholine (PS 100) used for these set of experiments. The maximum 
incorporation of these two isomers was 16%, obtained by Lipozyme RM IM after 72 h 
of reaction. Whereas, similar incorporation (about 15.5%) was obtained by Lipozyme 
TL IM after 48 h which then decreased to 11.6% after 72 h. Only 1.5% of total CLA 
isomers were incorporated by Novozym 435 even after 72 h of reaction. No isomers 
were detected in phosphatidylcholine catalyzed by Lipase F-AP15. Unlike other 
enzymes which were immobilized, Lipase F-AP15 was used without immobilization.  
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Table 7- Fatty acid composition of transesterified soy PC (PS 100) at different 
reaction times catalyzed by Lipozyme RM IM 
 
Fatty acid composition (% area)a 
 Substrate 
Modified PC 
Fatty acid PC Isomerized CLA 12 h 24 h 48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 13.7 
± 0.26 
11.5 
± 0.42 
10.8 
± 0.28 
9.5 
± 0.18 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 3.9 
± 0.19 
3.6 
± 0.16 
3.2 
0.08 
3.2 
± 0.11 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 10.5 
± 0.14 
11.3 
± 0.21 
13.4 
± 0.31 
13.6 
± 0.16 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 63.0 
± 0.77 
58.5 
± 0.91 
55.3 
± 0.56 
53.0 
± 0.47 
C18:3 6.6 
± 0.31 
- 6.8 
± 0.15 
6.7 
± 0.08 
4.9 
± 0.32 
4.4 
± 0.13 
c9,t11-CLA - 35.1 ± 1.1 1.1 
0.07 
4.0 
± 0.14 
5.7 
± 0.09 
8.0 
± 0.12 
t10,c12-CLA - 35.8 ± 1.3 1.1 
± 0.02 
4.4 
± 0.13 
6.6 
± 0.04 
8.0 
± 0.09 
   aMean ± standard deviation of three analyses. 
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Table 8- Fatty acid composition of transsterfied soy PC (PS 100) at different 
reaction times catalyzed by Lipozyme TL IM 
 
Fatty acid composition (% area)a 
 Substrate 
Modified PC 
Fatty acid PC Isomerized CLA 12 h 24 h 48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 12.9 
± 0.11 
11.9 
± 0.09 
9.4 
± 0.22 
12.1 
± 0.18 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 3.8 
± 0.16 
3.5 
± 0.10 
3.8 
± 0.10 
3.7 
± 0.17 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 10.5 
± 0.17 
11.8 
± 0.09 
12.6 
± 0.08 
11.3 
± 0.13 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 62.6 
± 0.61 
58.5 
± 0.44 
49.4 
± 0.72 
55.9 
± 0.39 
C18:3 
6.6 
± 0.31 
- 5.9 
± 0.13 
6.1 
± 0.07 
9.2 
± 0.14 
5.3 
± 0.11 
c9,t11-CLA - 35.1 ± 1.1 1.8 
± 0.02 
4.7 
± 0.04 
7.9 
± 0.09 
5.1 
± 0.11 
t10,c12-CLA - 35.8 ± 1.3 2.4 
± 0.04 
3.5 
± 0.07 
7.6 
± 0.06 
6.5 
± 0.06 
   aMean ± standard deviation of three analyses. 
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Table 9- Fatty acid composition of transsterfied soy PC (PS 100) at different 
reaction times catalyzed by Novozym 435 
 
Fatty acid composition (% area) 
 Substratea 
Modified PCb 
Fatty acid PC Isomerized CLA 12 h 24 h 48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 13.4 12.6 12.6 12.8 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 3.6 3.5 3.4 3.6 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 9.3 9.8 10.1 10.5 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 64.2 66.4 66.0 65.6 
C18:3 
6.6 
± 0.31 
- 8.8 6.7 6.5 6.0 
c9,t11-CLA - 35.1 ± 1.1 0.3 0.24 0.5 0.4 
t10,c12-CLA - 35.8 ± 1.3 0.25 0.7 0.8 1.1 
   aMean ± standard deviation of three analyses 
   bAverage of two analyses. 
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Table 10- Fatty acid composition of transsterfied soy PC (PS 100) at different 
reaction times catalyzed by Lipase F-AP15 
 
Fatty acid composition (% area) 
 Substratea 
Modified PCb 
Fatty acid PC Isomerized CLA 24 h 48 h 24 h* 48* h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 13.5 14.0 14.4 14.0 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 3.7 3.8 3.9 3.9 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 9.2 9.4 9.5 9.7 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 64.8 65.9 65.6 65.7 
C18:3 
6.6 
± 0.31 
- 8.8 6.7 6.7 6.6 
c9,t11-CLA - 35.1 ± 1.1 0.1 ND ND ND 
t10,c12-CLA - 35.8 ± 1.3 ND ND ND ND 
   aMean ± standard deviation of three analyses 
   bAverage of two analyses. 
   ND- Not detected 
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Tables 7 and 8 shows that CLA isomers were incorporated into 
phosphatidylcholine mainly with the exchange of linoleic acid (C18:2) and also with 
linoleneic acid (C18:3). Fatty acids other than these acids were randomly increased and 
decreased with time. This may be due to the complex reaction kinetics consisting of 
interesterification as well as hydrolysis of phosphatidylcholine. So, when CLA esterified 
into PC with exchange of existing acyl chains, lyso phsphatidylcholine (LPC, PC with 
one acyl chain cleaved off) was formed with time. The liberated fatty acids then acted as 
substrate for esterification reaction. The formation of lyso-PLs during acidolysis reaction 
of PLs was also reported by other authors (Peng and others 2002; Haraldsson and 
Thorarensen 1999). In our study, the qualitative TLC analysis of acidolysis reaction 
products between PC and CLA confirmed the formation of LPC with time (Figure 8). 
The reaction products were migrated on TLC plates as FA (fatty acids) > PC > LPC. No 
LPC spots were visualized in reaction products catalyzed by Lipase F-AP15. Also, we 
did not have any CLA incorporation into PC by this enzyme. Quantitative data of LPC 
was obtained from HPLC analysis of reaction products with time and %hydrolysis was 
calculated based on the relative amount of LPC present in the reaction products. Figure 9 
shows the hydrolysis ratio of two reactions catalyzed by Lipozyme RM IM and 
Lipozyme TL IM. The pattern of hydrolysis was similar for both the enzymes. The rate 
of hydrolysis was slow at the beginning and was almost constant at about 8% between 
24 and 48 h. After 48 h, the ratio increased rapidly to 19% at 72 h of reaction time.  
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Figure 8- TLC analysis of acidolysis reaction products between PC and CLA 
isomers by different enzymes at different times. 
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Figure 9- Degree of hydrolysis during acidolysis reaction. ■ catalyzed by 
Lipozyme RM IM; ♦-catalyzed by Lipozyme TL IM. 
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To monitor the reaction kinetics, we measured the fatty acid composition of LPC 
of reaction products at different times by preparative TLC. Tables 11 through 13 shows 
the fatty acid composition of lyso phosphatidylcholine. About 12.6% of total CLA 
isomers were incorporated into LPC after 48 h of reaction catalyzed by Lipozyme TL 
IM, which then decreased to 8.1% after 72 h. The composition of total CLA isomers in 
LPC catalyzed by this enzyme was higher than that of LPC catalyzed by other lipase 
enzymes (Lipozyme RM IM and Novozym 435). Fatty acid composition of palmitic acid 
(C16:0) and stearic acid (C18:0) decreased with reaction time. Lipozyme TL IM and 
Lipozyme RM IM preferentially cleaved acyl chain attached at position sn-1 of PC. 
According to the supplier, Lipozyme TL IM and Lipozyme RM IM are 1,3- position 
specific lipases and Novozym 435 is non-specific lipase. Unlike triacylglycerols where 
these 1,3 -position specific enzymes can exchange or cleave fatty acids from sn-1 and 
sn-3 positions, these enzymes can exchange or cleave fatty acids from position sn-1 only 
of phospholipids (PLs).  
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Table 11- Fatty acid composition of lyso-PC formed due to the hydrolysis of soy PC 
(PS 100) at different reaction times catalyzed by Lipozyme RM IM 
 
Fatty acid composition (% area) 
 Substratea 
Lyso-PC  
Fatty acid PC Isomerized CLA 12 h 
 
48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 7.1 2.7 5.6 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 5.6 0.7 1.4 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 19.7 11.2 15.3 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 57 74 67.4 
C18:3 
6.6 
± 0.31 
- 7.1 7.7 7.4 
c9,t11-CLA - 35.1 ± 1.1 0.3 1.3 0.9 
t10,c12-CLA - 35.8 ± 1.3 0.4 2.0 2.1 
   aMean ± standard deviation of three analyses 
   bAverage of two analyses. 
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Table 12- Fatty acid composition of lyso-PC formed due to the hydrolysis of soy PC 
(PS 100) at different reaction times catalyzed by Lipozyme TL IM 
 
Fatty acid composition (% area) 
 Substrate 
Lyso-PC 
Fatty acid PC Isomerized 
CLA 
12 h 24 h 48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 4.0 3.9 4.0 4.9 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 1.7 1.1 1.4 1.4 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 10.8 11.4 11.1 13.4 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 71.7 71.6 64.0 66.5 
C18:3 
6.6 
± 0.31 
- 8.1 7.0 6.8 5.6 
c9,t11-CLA - 35.1 ± 1.1 1.0 1.6 5.0 3.0 
t10,c12-CLA - 35.8 ± 1.3 2.5 3.3 7.6 5.1 
   aMean ± standard deviation of three analyses 
   bAverage of two analyses 
 
 
 
 
 
 
 
 
     
57
 
 
Table 13- Fatty acid composition of lyso-PC formed due to the hydrolysis of soy PC 
(PS 100) at different reaction times catalyzed by Novozym 435 
 
Fatty acid composition(% area) 
 Substratea 
Lyso-PCb 
Fatty acid PC Isomerized CLA 12 h 24 h 48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 4.2 3.6 3.9 4.7 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 4.2 1.3 1.2 1.4 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 9.4 10.0 11.3 11.5 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 71.4 72.9 73.4 72.1 
C18:3 
6.6 
± 0.31 
- 7.9 11.3 7.4 6.7 
c9,t11-CLA - 35.1 ± 1.1 ND ND 0.6 1.6 
t10,c12-CLA - 35.8 ± 1.3 0.2 0.8 1.7 2.0 
   aMean ± standard deviation of three analyses 
   bAverage of two analyses 
   ND-not detected 
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4.2.2 Phospholipase A2 (PLA2) catalyzed acidolysis reaction 
Phospholipase A2 (PLA2) has specificity for sn-2 position of PLs and it has been 
applied for incorporating highly unsaturated fatty acid into sn-2 position of PC by 
transesterification reaction (Hosokawa and others 1998). They reported about 26% 
incorporation of eicosapentaenoic acid (EPA) into soy PC after 72 h. In our study we 
have only 4.2% incorporation (Table 14) of CLA into PC in a similar reaction between 
PC and CLA catalyzed by PLA2 in 72 h. In that earlier study, they used freeze-dried 
PLA2 after dialysis. Also, the reaction was carried out in glycerol medium. But, in our 
study we used immobilized (Celite was used as carrier) PLA2 in hexane. Surprisingly, 
we have noticed an increase in palmitic (C16:0) acid in transesterified PC with time. The 
palmitic acid concentration was 18.3% in PC after 72 h. Similarly, the fatty acid 
composition of stearic (C18:0) and oleic (C18:1) acids increased with the decrease of 
linoleic (C18:2) and lioleneic (C18:3) acids with time. However, Svensson and others 
(1990) showed that immobilized (Celite) PLA2 did not catalyze the interesterification 
reaction between PC and heptadecanoic acid in toluene. But, they did not report about 
the change in other fatty acids composition with time. More research is needed to 
identify whether the presence of organic solvent changes the sn-2 positional specificity 
of PLA2.  
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Table 14- Fatty acid composition of transsterfied soy PC (PS 100) at different 
reaction times catalyzed by phospholipase A2 enzyme (Lecitase 10 L) 
 
Fatty acid composition (% area)a 
 Substrate 
Modified PC 
Fatty acid PC Isomerized CLA 12 h 24 h 48 h 72 h 
C16:0 12.8 
± 0.21 
6.7 ± 0.32 15.2 
± 0.26 
16.4 
± 0.42 
17.9 
± 0.28 
18.3 
± 0.83 
C18:0 3.5 
± 0.14 
2.5 ± 0.22 4.1 
± 0.19 
4.3 
± 0.16 
4.6 
± 0.21 
5.7 
± 0.19 
C18:1 10.7 
± 0.34 
15.4 ± 0.61 12.1 
± 0.15 
13.3 
± 0.12 
13.9 
± 0.36 
14.2 
± 0.15 
C18:2 66.4 
± 1.06 
1.7 ± 0.11 59.4 
± 0.22 
58.7 
± 0.55 
55.8 
± 0.94 
53.1 
± 1.15 
C18:3 
6.6 
± 0.31 
- 5.7 
± 0.08 
5.7 
± 0.23 
5.2 
± 0.12 
3.5 
± 0.32 
c9,t11-CLA - 35.1 ± 1.1 ND 0.9 
± 0.07 
1.3 
± 0.08 
2.2 
± 0.06 
t10,c12-CLA - 35.8 ± 1.3 ND 0.8 
± 0.04 
1.2 
± 0.07 
2.0 
± 0.08 
   aMean ± standard deviation of three analyses. 
 
 
 
 
 
 
 
 
     
60
4.2.3 Lipase and phospholipase A2 catalyzed acidolysis reaction 
 As part of our effort for enzyme screening to get maximum incorporation of CLA 
into phospholipids with higher yield, we investigated the acidolysis reaction between 
CLA and soy PC catalyzed by mixture of lipase and phospholipase A2 enzymes. Results  
are shown in Figures 10 and 11 in terms of % incorporation of CLA into PC and lyso PC 
with time. For comparison, we included the rate of incorporation of CLA by lipases and 
phospholipase A2 alone. Though it was expected, Figure10 shows that the rate of 
incorporation did not increase by the enzyme mixture. The rate was higher by Lipozyme 
RM IM and Lipozyme TL IM than by their mixture with phospholipase A2. But the 
mixture of Lipozyme TL IM and Lipozyme RM IM with phospholipase A2 (Lecitase    
10 L) had higher rate of incorporation than it was by Lecitase 10 L and Novozym 435 
alone. Among the mixture of two lipases and phospholipase A2, the rate of incorporation 
was much higher by Lipozyme TL IM and Lecitase 10 L than that by Lipozyme RM IM 
and Lecitase 10 L at early hours. But after 72 h both the mixture had similar 
incorporation rate. Aura and others (1995) reported that the mixture of lipase and 
phospholpase A2 incorporated lauric acid (C12:0) to the same extent as 1,3-specific 
lipase (Lipozyme IM-60) incorporated alone. Figure 11 shows the rate of incorporation 
of CLA into lyso PC by these enzymes. The rate of incorporation was higher by mixture 
of Lipozyme TL IM and Lecitase 10 L compared to others for the first 24 h but then the 
rate increased with time in the case of Lipozyme TL IM alone. However, the rate was 
higher by the mixture of lipases and phospolipase A2 than it was by Lipozyme RM IM 
and Novozym 435 alone. Several factors, including the interaction of different carriers 
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used for enzyme immobilization, relative enzyme specificity in presence of others, and 
water availability, might be responsible for this. More details study of reaction kinetics is 
needed to address this behavior which is not tried in this study. 
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Figure 10- Comparison of enzymes in terms of rate of incorporation of CLA into 
PC. ■, Lipozyme TL IM; ♦, Lipozyme RM IM; ▲, Lipozyme TL IM and Lecitase  
10 L; ●, Lipozyme RM IM and Lecitase 10 L; ∗, Novozym 435; ×, Lipase F-AP15. 
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Figure 11- Comparison of enzymes in terms of rate of incorporation of CLA into 
lyso PC. ♦, Lipozyme TL IM; ■, Lipozyme TL IM and Lecitase 10 L; ●, Lipozyme 
RM IM and Lecitase 10 L;▲,Lipozyme RM IM; ×, Novozym 435. 
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4.3 Synthesis of structured phospholipids with CLA from different sources 
 Phospholipids from different sources with different fatty acids composition and 
classes of phospholipids have very specific functional and physiological properties. The 
effect of phospholipid sources and different pospholipid classes on the rate of 
incorporation of CLA into phospholipids by enzyme catalyzed acidolysis reaction was 
investiated. Soybean and egg yolk phospholipids with varying content of 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were used for this 
purpose. Figure 12 shows the effects of source and class of phospholipids on the rate of 
incorporation of CLA. The content of PC in individual lipid class has higher effect on 
rate of incorporation. The rate is directly proportional to PC content. The soybean 
phospholipids (soy-PL) with more than 94% PC content had 16% total CLA isomers 
incorporated into PLs. Whereas, the soyPL with about 20% PC content had only 3.5% 
incorporation. Similarly, egg phospholipids (egg-PL) with more than 98% PC content 
had about 13.6% CLA isomers incorporated compare to 7% in egg-PL with 80% PC 
content. Egg phospholipids prepared from fresh egg yolk in our facilities had similar rate 
of incorporation of total isomers (7.4%) like commercial egg-PL with 80% PC. The 
amount of PC in our prepared egg-PL was about 78%. The soy PC has higher rate of 
CLA incorporation than egg PC (Figure 12). This may be due to the difference in inter -
molecular packing because of their difference in fatty acids composition. Further 
research is needed before an explanation is made. Table 15 shows the incorporation of 
CLA in different classes of phospholipids. PC has higher rate of incorporation than PE 
with time. Similar results were reported by Peng and others (2002). 
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Figure 12- Effect of different phospholipids on the incorporation of CLA. Bars with 
similar letter are not statistically significant (α = 0.05). SoyPL_94% PC, soybean 
phosphatidylcholne w/ 94% PC. SoyPL_20% PC, Regular deoiled soybean 
lecithins. EggPL_98%PC, egg phosphatidylcholine w/ 98% PC. EggPL_80%, 
deoiled egg lecithin. EggPL-prepared, Deoiled egg yolk lecithin prepared in the lab. 
These reactions were catalyzed by Lipozyme RM IM for 72 h. 
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Table 15- Incorporation of CLA isomers in different classes of phospholipids. 
Deoiled egg yolk lecithin catalyzed by Lipozyme RM IM was used for this study. 
Phospholipid classes separated on TLC plate was methylated for fatty acid 
composition 
 Incorporation of CLA isomers (%) 
 PC PE 
Reaction time (h) c9,t11-CLA t10,c12-CLA c9,t11-CLA t10,c12-CLA 
24 1.7 1.4 0.4 0.3 
48 2.9 2.7 1.2 1.3 
72 6.3 6.4 2.9 3.0 
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4.4 Optimization of incorporation of CLA into phospholipids 
4.4.1 Model fitting 
 The primary objective of this study was to maximize the incorporation of CLA 
into phospholipids. The central composite rotatable design, the best design for response 
surface optimization, was selected with four parameters, i.e. lipase dosage, substrate 
ratio, reaction time and temperature. Table 16 lists the experimental parameter settings 
and results of incorporation of CLA into phospholipids based on the experimental 
design. The best fitting model was determined by regression and backward elimination. 
The model coefficients (β) and probability (P) values are given in Table 17. Among all 
the possible regression models i.e. linear, quadratic, cross product, and combination of 
all, linear model was highly significant (P-value 0.0004) with coefficient of 
determination (R2) 0.68. Though the quadratic and cross product P-values were 0.125 
and 0.703 respectively, the total model (equation 1) was highly significant (P-value 
0.0080) with R2 value 0.8526. According to the analysis of variance, the P-value for lack 
of fit was 0.0869. The observed values and predicted values of incorporation of CLA 
into PC based on this model were sufficiently correlated (Figure 13). As formation of 
lyso PC (LPC) because of hydrolysis of PC was observed along with the 
interesterification reaction, we applied response surface methodology to identify the 
reaction parameters to optimize the CLA incorporation as well as yield. The values of 
LPC are listed in the Table 15. The observed values and predicted values of LPC based 
on this model were also correlated (Figure 14). The model that is best suited for these 
selected ranges can not be extrapolated. 
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Table 16- Experimental setup for four-factor, three-level response surface design 
and the response after analysis 
Variable (actual) Experiment 
Ed Sr Te ti 
Incorporation 
of CLA into 
PC
Formation of 
lyso PC (LPC) 
(%)
1 15 3.5 50 30 4.10 12.32 
2 25 3.5 50 30 7.20 10.53 
3 15 6.5 50 30 7.60 5.44 
4 25 6.5 50 30 10.20 10.89 
5 15 3.5 60 30 5.15 11.78 
6 25 3.5 60 30 8.30 8.91 
7 15 6.5 60 30 9.40 7.74 
8 25 6.5 60 30 9.70 12.13 
9 15 3.5 50 70 7.85 16.69 
10 25 3.5 50 70 8.55 14.28 
11 15 6.5 50 70 6.25 9.11 
12 25 6.5 50 70 12.85 13.94 
13 15 3.5 60 70 6.20 18.38 
14 25 3.5 60 70 7.30 14.88 
15 15 6.5 60 70 6.95 13.65 
16 25 6.5 60 70 11.40 17.40 
17 10 5.0 55 50 6.40 11.12 
18 30 5.0 55 50 13.10 13.09 
19 20 2.0 55 50 4.85 18.04 
20 20 8.0 55 50 11.80 13.67 
21 20 5.0 45 50 5.35 7.85 
22 20 5.0 65 50 6.05 10.76 
23 20 5.0 55 10 3.35 7.43 
24 20 5.0 55 90 10.25 17.08 
25 20 5.0 55 50 9.10 15.70 
26 20 5.0 55 50 8.85 15.70 
27 20 5.0 55 50 8.45 14.67 
28 20 5.0 55 50 8.13 14.01 
Abbreviations: Ed, lipase dosage (wt.% of phospholipids); Sr, substrate ratio (CLA/PL, 
mol/mol); Te, reaction temperature (oC); ti, reaction time (h). 
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Table 17- Regression coefficient (β) and significance (P-value) of the polynomial 
model of RSM for incorporation of CLA into PC 
Parameters Coefficient (β)       P-value 
Intercept                                8.975000                     <.0001 
Ed                                          1.475000                     0.0006 
Sr                                           1.400000                     0.0008 
Te                                           0.050000                    0.8739 
 ti                                           0.812500                     0.0230 
Ed*Ed                                     0.263542                     0.4804 
Sr*Ed                                      0.368750                     0.3489 
Sr*Sr                                      -0.092708                    0.8020 
Te*Ed                                     -0.250000                    0.5208 
Te*Sr                                      0.081250                     0.8332 
Te*Te                                     -0.748958                    0.0622 
ti*Ed                                       0.231250                    0.5519 
ti*Sr                                      -0.287500                    0.4616 
ti*Te                                      -0.443750                   0.2639 
ti*ti                                        -0.473958                   0.2157 
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Figure 13- Relationship between the observed and predicted incorporation of CLA 
into phospholipids catalyzed by Lipozyme TL IM. Values inside the figure are from 
experimental settings. 
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Figure 14- Relationship between the observed and predicted values of lyso PC 
formation (LPC) because of hydrolysis during acidolysis reaction catalyzed by 
Lipozyme TL IM. 
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4.4.2 Effects of different parameters on CLA incorporation 
 
 The effects of all parameters on the incorporation of CLA and their significance 
are shown in Figure 15. All first-order coefficients have positive effects on the 
incorporation. Some second-order coefficients have positive effects and some have 
negative effects. So, the relationship between the factors and the response was not linear. 
The enzyme load (Ed) had the most significant effect followed by substrate ratio (Sr) and 
reaction time (ti) respectively. The temperature (Te) had smaller effect but square of Te 
had highest negative effects. The individual effect of four factors on the incorporation is 
given in Figure 16 through 19. As expected, incorporation was improved by longer 
reaction time (Figure 16). The incorporation was maximum around 60 h but in the single 
study catalyzed by this enzyme, we had higher incorporation at 48h compare to 72 h 
(Table 8). Lipase dosage caused a positive linear increase in the extent of CLA 
incorporation (Figure 17). The incorporation of CLA increased with increasing substrate 
ratio up to a ratio of around 6 (Figure 18). Excessive free fatty acids may result in 
enzyme inhibition. The effect of temperature on incorporation had showed highly bell-
shaped curve (Figure 19). The optimum reaction temperature was 55oC after which the 
rate decreased very fast. Enzymes might be deactivated at higher temperature. 
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Figure 15- Factor effects and their significance on the incorporation of CLA into 
phospholipids catalyzed by Lipozyme TL IM. For abbreviation, see Table 5.  
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Figure 16- Effect of reaction time on the incorporation of CLA into phospholipids 
catalyzed by Lipozyme TL IM. 
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Figure 17- Effect of enzyme load on the incorporation of CLA into phospholipids 
catalyzed by Lipozyme TL IM. 
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Figure 18- Effect of substrate ratio on the incorporation of CLA into phospholipids 
catalyzed by Lipozyme TL IM. 
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Figure 19- Effect of reaction temperature on the incorporation of CLA into 
phospholipids catalyzed by Lipozyme TL IM. 
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4.4.3 Optimization of reaction system 
 From the economic point of view, the most efficient conditions for this reaction 
would be to use the lowest amount of enzyme load and at the lowest temperature with 
the lowest substrate ratio to achieve the highest incorporation of CLA. Though the single 
factor plot shows the value or trend to get the maximum incorporation, the three 
dimensional response surfaces generated by using linear, quadratic and cross-product 
terms in the second order polynomial give the desirable combination of variables that 
can be selected to obtain the highest incorporation at the least cost. The response 
surfaces generated for our study are shown in Figures 20 through 25. Figure 20 shows 
that the rate of incorporation could be increased by increasing time and enzyme load 
while keeping the temperature and substrate ratio constant. Figures 21 and 22 show that 
change in temperature in any direction from center point would decrease the rate of 
incorporation of CLA. But increase of substrate ratio will increase the rate at any 
temperature while keeping time and enzyme load constant (Figure 21). Similarly, Figure 
23 shows that the maximum rate at center value of temperature and time which are 55oC 
and 50 h. Figure 24 shows that rate can be increased by increasing enzyme load and 
substrate ratio while keeping time and temperature constant. Figure 25 shows that 
substrate ratio increased the rate with time up to certain value after which it started 
decreasing. The overall shape of the response surfaces and the canonical analysis of SAS 
software identified the stationary points of this model as saddle points which are neither 
maximum nor minimum.  
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Figure 20- Response surface showing the effect of enzyme load and time with 
temperature and substrate ratio held constant at 55oC and 5.0 respectively. 
 
 
 
 
Figure 21- Response surface showing the effect of substrate ratio and temperature 
with enzyme load and time held constant at 20 (wt.%) and 50 h respectively. 
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Figure 22- Response surface showing the effect of enzyme load and temperature 
with substrate ratio and time held constant at 5 and 50 h respectively. 
 
 
 
 
Figure 23- Response surface showing the effect of temperature and time with 
substrate ratio and enzyme load held constant at 5 and 20 (wt.%) respectively. 
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Figure 24- Response surface showing the effect of enzyme load and substrate ratio 
with time and temperature held constant at 50 h and 55oC respectively. 
 
 
 
 
Figure 25- Response surface showing the effect of substrate ratio and time with 
enzyme load and temperature held constant at 20 (wt.%) and 55oC respectively. 
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4.5 Applications of newly synthesized structured phospholipids in foods and their 
physiological properties 
 
The ultimate objective of this study was to produce structured phospholipids for 
use as nutaceuticals and functional food ingredients. Our initial efforts to use them in 
food system served to asses whether they can provide functional properties as well as 
bioactive properties in foods. 
 
4.5.1 Emulsifying properties of structured phospholipids 
 There is an increasing interest in the use of phospholipids as natural emulsifier. 
Thus the utility of any structured phospholipids will depend upon its ability to act as an 
emulsifier. For this reason the emulsifying capacities of CLA containing structured 
phospholipids was tested. The materials were used in efforts to stabilize whey protein 
based emulsion during both heat and oxidative stability tests. Whey proteins are usually 
heat unstable. So, whey protein based emulsions need to be stabilized by a means before 
any heat treatment like retort processing. Structured phospholipids with two levels of 
CLA incorporation derived from two sources (egg yolk and soy PC) were compared for 
their emulsifying properties. Whey protein based emulsion with 16% CLA containing 
soy PC (PS 100) showed highest heat stability even after heating at 121oC for 15 min 
(Figures 26 and 27). Heat stability was assessed based on the mean particle size 
distribution of emulsion before and after heating. Emulsion with CLA-PS 100 had 
smaller mean particle size distribution compare to others. The particle size distribution 
was similar before and after heating. But, emulsions with controls and CLA containing  
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Figure 26- Particle size distribution of emulsions before heating. PE 80 egg 
phospholipids (80% PC), PS 100- soy PC (94% PC), CLA-PE 80- CLA containing 
PE 80 (7% CLA), CLA-PS 100- CLA containing PS 100 (16% CLA), control- 
emulsion without phospholipids. Control, emulsion without any lecithin. 
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Figure 27- Particle size distribution of emulsions after heating. For abbreviations, 
see Figure 26. 
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egg PC (7% CLA) had higher mean particle size distribution which increased after 
heating because of disintegration of emulsions.  
Oxidative stability was determined by measuring peroxide value (PV) and p-
anisidine (p-AV) value of emulsions incubated at 50oC on day 1, day 3 and day 7 after 
preparation. Emulsions with CLA phospholipids from both egg yolk and soy PC had 
lower PV and p-AV values even after 7 days compared to their controls (Figures 28 and 
29). Values are about 4 times lower than their corresponding controls. 
 
4.5.2 Physiological properties of CLA containing structured phospholipids 
 As numerous physiological properties have been attributed to CLA, we studied 
the anticarcinogenic properties of CLA containing structured phospholipids from two 
sources (egg yolk and soy PC) in tumor cells. Table 18 shows some preliminary results 
with melanoma skin tumor cells. We compared the CLA isomers as free fatty acids in 
Caco-2 cancer cells (Table 19). Table 18 shows that level of CLA incorporated into soy 
phospholipids (94% PC) has direct effect on cell suppression. The cell suppression was 
higher for the higher rate of CLA incorporation. Source of phospholipid with similar 
CLA incorporation has some effect in terms of the dose of test sample. More research is 
needed to confirm this result. The cell suppression was defined as the difference between 
the final count of viable cells after incubating with test samples and the corresponding 
seeding population before incubation. 
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Figure 28- Oxidative stability (peroxide value) of emulsion. Incubation at 50oC for 
day 1 , day 3, day 7. PE 80 egg phospholipids (80% PC), PS 100- soy PC (94% 
PC), CLA-PE 80- CLA containing PE 80 (7% CLA), CLA-PS 100- CLA containing 
PS 100 (16% CLA), control- emulsion without phospholipids. Bars with similar 
letter are not statistically significant (α = 0.05).  
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Figure 29- Oxidative stability (p-anisidine value) of emulsion. Incubation at 50oC 
for day 1 , day 3, day 7. PE 80 egg phospholipids (80% PC), PS 100- soy PC (94% 
PC), CLA-PE 80- CLA containing PE 80 (7% CLA), CLA-PS 100- CLA containing 
PS 100 (16% CLA), control- emulsion without phospholipids. Bars with similar 
letter are not statistically significant (α = 0.05). For abbreviations- see Figure 26. 
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  Table 18- Suppression of murine B16 melanoma skin tumor cells by CLA-PL 
Samples Phospholipid 
source 
c9,t11- CLA 
+ t10,c12- CLA 
% control growth 
(mean ± SD, n=4) 
Solvent  - 100 ± 3 
CLA-PS100, 0.25 mM Soybean PC 4.0% 95 ± 7 
CLA-PE80, 0.15 mM Egg yolk 3.6% 84 ± 5 
CLA-PS100, 0.06 mM Soybean PC 16.0% 45 ± 2 
For abbreviations: see Figure 26 
   
  Table 19- Suppression of Caco-2 colon cancer cells by CLA isomers 
Samples 
c9,t11- CLA 
+ t10,c12- CLA % control growth 
(mean ±SD, n=4) 
Solvent - 100 ± 3 
CLA isomers, 0.1% 
(35% c9t11, 35% t10c12) 
70% 38 ± 2 
For abbreviations: see Figure 26 
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4.6 Summary 
 
 Enzymatic processes proved an effective technique to modify fatty acid 
composition and head group of phospholipids. Lipase catalyzed acidolysis reaction 
successfully incorporated CLA into egg yolk and soy phospholipids. Among the four 
lipases, Lipozyme RM IM, Lipozyme TL IM, Novozym 435, and Lipase F-AP15 and an 
immobilized phospholipase A2 tested, only Lipozyme TL IM and Lipozyme RM IM 
showed higher CLA incorporation. From commercial point of view, Lipozyme TL IM 
will be the best choice for incorporation of CLA into phospholipids. The cost of 
Lipozyme TL IM is lower than others as low cost silica based materials are used for 
immobilization. The different classes of phospholipids had different rates of 
incorporation. The rate of incorporation is much higher in phospholipids with high level 
of PC and lowest in phospholipids with lowlevel od PC. CLA containing lyso- 
phospholipids were formed due to hydrolysis reaction and possibly acyl migration. 
Positional specificity (1,3 position specific) of lipase was retained as CLA was 
preferentially incorporated in sn-1 position of phospholipids. Two major bioactive 
isomers of CLA were equally incorporated into phospholipids. Polynomial regression 
equation using response surface method satisfactorily predicted the rate of incorporation 
of CLA against the actual experimental values (R2 0.85) with regard to enzyme dosage, 
substrate ratio, reaction time and temperature. The best operating conditions to achieve 
the highest rate of incorporation catalyzed by Lipozyme TL IM are as 30% enzyme load, 
6 (mol CLA/mol PL) substrate ratio, 60 h reaction time and temperature 55oC. CLA 
containing structured phospholipids can provide higher heat stability and oxidative 
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stability of food emulsion systems. Also, CLA incorporated phospholipids may offer 
versatile dietary source of CLA with higher chemo preventive effects specially in 
anticarcinogenesis  
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CHAPTER V 
 
 
LITERATURE REVIEW: SYNTHESIS OF STRUCTURED PHOSPHOLIPIDS  
WITH PLANT STEROLS 
 
 
 
5.1 Sterols 
 
Sterols are essential compounds for all eukaryotes. Mammalian cells generally 
contain one major sterol, cholesterol; but mixtures of sterols are always present in plants 
(Yeagle 1985; Hartmann 1998). So far, over 200 different plant sterol molecules have 
been found in nature. Sterols are cell membrane components that regulate the membrane 
fluidity and permeability and participate in the control of membrane-associated 
metabolic processes. Sterols are also precursors for several other compounds involved in 
important cellular and developmental processes in animals and higher plants. Sterol 
molecules consist of a planar tetracyclic skeleton, a hydroxyl group and a hydrophobic 
tail. Most of the sterol molecule is hydrophobic, but the polar hydroxyl group gives the 
molecule an amphiphilic character.  
 
5.1.1 Cholesterol 
Although cholesterol is essential for normal cell growth and function, a high 
concentration of cholesterol in serum and tissues can be harmful. Epidemiological, post 
mortem, and angiographic studies have established a casual relation between elevated 
serum cholesterol levels (>5 mmol/1) and genesis of atherosclerosis and thus 
cardiovascular diseases, which are the major cause of morbidity and mortality in western 
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societies (Levine and others 1995; Sullivan 2002). In addition to atherosclerotic lesions, 
elevated cholesterol levels play an important role in the genesis of cholesterol gallstones 
(Strasberg 1998). Cholesterol is practically insoluble in water and thus it is associated 
with different vehicles in the human body. Cholesterol is either solubilized in bile salt 
micelles or associated with different phospholipid vesicles or with lipoprotein particles 
as free cholesterol or as cholesterol fatty acids esters (Montet and Gerolami 1978; 
Staggers and others 1990; Mensink and others 1998). When the cholesterol 
concentration exceeds the dissolution capacity of these vehicles, cholesterol crystals may 
be deposited. Solid cholesterol crystals are found in gallstones (Admirand and Small 
1968; Lundberg 1985; Small and Shipley 1974).  
 
5.1.2 Plant sterols 
Plant sterols are structurally related to cholesterol, and the most common plant 
sterols, β-sitosterol, campesterol and stigmasterol differ from cholesterol by an 
additional ethyl or methyl group and/or a double bond in side chain (Figure 30). 
Saturated plant stanols, such as β-sitostanol, are formed when the double bond is 
saturated. Although a typical dietary intake of plant sterols is almost equal to a dietary 
intake of cholesterol only small amounts of plant sterols are commonly detected in 
human plasma (Jones and others 1997). Serum β-sitosterol and campesterol levels are 
normally about 1/1000 and 2/1000 of that of cholesterol, respectively (Kuksis, 2001). 
Increased plasma levels of plant sterols can occur in individuals who suffer from 
sitosterolemia, which is an extremely rare inherited disorder caused by reduced plant 
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sterol excretion. The reduction of sterol excretion was caused by the mutations in two 
adjacent genes that encode ATP-binding cassette (ABC) transporter in patients with 
sitosterolemia (Berge and others 2000). In sitosterolemic patients, up to 30% of serum 
and bile sterols are plant sterols (Mietinen 1980). Similar to cholesterol, abnormally high 
plasma plant sterol concentration has been found to be atherogenic (Glueck and others 
1991). 
 
 
 
 
 
Figure 30- Structure of different sterols. 
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5.1.3 Cholesterol lowering effect of plant sterols 
The recent interest in plant sterols, especially in β-sitosterol and its saturated 
form β-sitostanol, is due to their cholesterol lowering effect. The cholesterol lowering 
effect of plant sterols has been known since the 1950s, but poor solubility of these 
materials and discovery of more effective cholesterol lowering agents limited the interest 
in them. In the 1990s foods containing plant sterols and stanols as active ingredients 
came on the European market (Law 2000). The promising cholesterol-lowering results 
of these products have raised interest in plant sterols and stanols. 
Free plant sterols and stanols are crystalline, insoluble in water with limited solubility in 
edible fats and oils (Jandacek and others 1977; Mattson and others 1977). Thus physico-
chemical properties of free plant sterols and stanols limit their applicability in several 
preparations suitable for oral administration.  
 
5.1.4 Cholesterol metabolism in human body 
Cholesterol level in the human body is maintained by balancing cholesterol 
absorption, endogenous synthesis and excretion. Important regulatory mechanisms 
involve (1) intestinal cholesterol absorption, (2) hepatic cholesterol synthesis, (3) 
conversion of cholesterol to bile acids in the liver, (4) biliary secretion of free cholesterol 
and (5) fecal elimination of steroids of cholesterol origin (Kesäniemi and Miettinen, 
1988). 
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5.1.4.1 Intestinal absorption 
The average dietary intake of cholesterol in western countries is 300-500 mg per 
day (Sehayek and others 1998). In addition to dietary cholesterol, 800-1200 mg 
cholesterol is excreted daily from the biliary duct into the intestine. A variable 
proportion of dietary cholesterol is essential (on average 10-15%) esterified with fatty 
acids, but all biliary cholesterol is non-esterified and incorporated into bile salt-
phospholipid micelles (Shen and others 2001). The efficacy of cholesterol absorption 
(percent cholesterol absorption) in normal healthy individuals is on average 50% of the 
ingested amount (Bosner and others 1999). Individual subjects have marked differences 
in cholesterol absorption (ranging from 29% to 80%), but variability in repeated 
cholesterol absorption studies in the same individual is small (Bosner and others 1993; 
Bosner and others 1999).  
A decrease in the percent cholesterol absorption with increasing dietary 
cholesterol has been observed in both animal and human studies (Ellegård and Bosaeus, 
1994; Sehayek and others 1998; Ostlund and others 1999a). Increased dietary cholesterol 
intake increases biliary cholesterol concentration, which decreases the absorption of 
dietary cholesterol. The saturation of cholesterol absorption by either increased dietary 
cholesterol ingestion or increased excretion of biliary cholesterol into the intestine 
occurs by saturation of solubilization capacity of the mixed micelles (Sehayek and others 
1998). 
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5.1.4.2 Endogenous synthesis 
The main site of cholesterol synthesis is the liver (Stryer 1995; Li and Parish 
1998). Appreciable amounts are also synthesised by the intestine. In addition, other 
tissues are able to synthesize cholesterol, but the primary cholesterol source of tissues 
other than the liver and intestine is plasma LDL cholesterol particles. The rate-limiting 
enzyme in the cholesterol biosynthesis is 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMG-CoA reductase). 
The rate of cholesterol synthesis in the liver is highly dependent on the amount of 
cholesterol absorbed in the intestine (Kesäniemi and Grundy 1984; Kesäniemi and 
Miettinen 1988). Inhibition of cholesterol absorption will decrease the quantity of 
cholesterol returning to the liver with chylomicron remnants. As a result of the reduction 
of liver cholesterol, a compensatory increase in the synthesis of LDL receptors takes 
place. Consequently, the uptake of LDL from circulation is enhanced and a decrease in 
serum LDL and total cholesterol is observed. On the contrary, overloading of the liver 
cells with cholesterol results in reduction of hepatic cholesterol synthesis regulated by 
the HMG-CoA reductase enzyme. The activity of hepatic LDL receptors decreases and 
receptor mediated removal of LDL from plasma lowered which results in increased 
plasma LDL levels (Kesäniemi and Miettinen 1988). This feedback regulation is 
mediated by changes in the activity of HMG-CoA reductase. On the other hand, low 
hepatic cholesterol and bile acid synthesis and/or diminished biliary cholesterol secretion 
leads to a lower intestinal load of cholesterol and thus enhances the intestinal absorption 
of cholesterol and vice versa. 
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5.1.5 Proposed cholesterol lowering mechanism of plant sterols 
It was assumed that the serum cholesterol lowering effect of plant sterols resulted 
from the inhibition of cholesterol absorption from the intestinal lumen (Moghadasian 
and Frohlich, 1999). The typical dietary intake of plant sterols is almost equal to the 
dietary intake of cholesterol (Ling and Jones 1995). In addition to cholesterol from 
dietary sources, two thirds of the cholesterol present in the intestinal lumen is 
endogenous cholesterol from bile (Wilson and Rudel 1994). When effective doses (1-3 
g/day) of β-sitosterol or plant sterols mixtures are consumed, the ratio of cholesterol to 
plant sterol entering the intestinal lumen is about 1:1. Besides inhibiting the absorption 
of cholesterol, plant sterols affect enzymes involved in cholesterol metabolism (Ling and 
Jones 1995; Moghadasian and Frohlich 1999). The actual mechanism by which the plant 
sterols and stanols reduce cholesterol absorption has not been confirmed. Several 
molecular mechanisms of phytosterol action on serum cholesterol level are believed to 
be of particular importance (Trautwein and others 2003). 
 
5.1.5.1 Mixed crystal formation of β-sitosterol and cholesterol 
It was observed that cholesterol and β-sitosterol formed a mixed crystal from 
which the two components could not be separated by recrystallisation (Pollak 1953). 
Davis (1955) observed that cholesterol and β-sitosterol formed a new crystal form when 
1:1 mixture of the sterols was precipitated from methanol. The solubility of the new 
crystal in methanol was considerably lower than that of cholesterol but higher than that 
of β-sitosterol. Davis concluded that the conversion of cholesterol in the intestine into a 
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less dispersible form by the formation of mixed crystal with sitosterol might be the 
primary mechanism reducing cholesterol absorption. A later in vitro study confirmed 
that cholesterol and β-sitosterol form a solid solution at 1:1 molar ratio when crystallized 
from either methanol or ethanol (Karpuj and others 1982). 
 
5.1.5.2 Restriction of the solubility of cholesterol in the intestinal micellar phases 
According to the mechanism presented by Mattson and others (1982), absorption 
of cholesterol is determined by the total sterol concentration (cholesterol plus plant 
sterols) in the intestinal fat. It is thought that β-sitosterol reduces the solubility of 
cholesterol in oil presumably by competing for solubility sites (Wright and Presberg 
1964). When the sterol solubility in oil is exceeded, solid sterols crystallize and 
precipitates are not absorbed. The composition of the precipitated sterols in the intestine 
reflects that of the oil phase. In the lumen of the intestine, sterols are distributed between 
micellar and oil phases. The surface activity of the free sterols causes them to 
accumulate at the oil/water interface. At the interface, the transfer of the sterols to the 
micellar phase and their crystallization are facilitated. Thus, high intake of plant sterol 
increases the fecal excretion of neutral sterols (Westrate and others 1999).  
According to Armstrong and Carey (1987), the binding of β-sitosterol to tri-
hydroxy bile salt micelles is energetically favored compared with cholesterol. Both β-
sitosterol and β-sitostanol decreased the micellar solubility of cholesterol and reduce the 
concentration of cholesterol in mixed bile salt micelles, both in vitro and in vivo (Ikeda 
and Sugano 1983; Ikeda and others 1988; Ikeda and others 1989). In general, the 
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competition for the micellar solubilization capacity of bile salts may regulate the 
absorption of different sterols in the intestinal lumen. For example, plant stanols prevent 
the absorption of plant sterols in addition to cholesterol, resulting in a lowering of the 
respective serum levels of sterols, but even a twofold increase in serum plant stanol 
levels is observed (Gylling and others 1999a; Gylling and Miettinen 1999; Hallikainen 
and others 2000a). 
 
5.1.5.3 Competitive inhibition of cholesterol uptake by intestinal mucosal cells 
The early studies suggested that β-sitosterol could restrict the absorption of 
cholesterol by competitive inhibition of the uptake by intestinal mucosal cells (Glover 
and Green 1957). According to later studies, β-sitosterol does not affect the uptake of 
cholesterol from micellar solutions or the esterification of cholesterol by the mucosal 
cells (Ikeda and Sugano 1983; Field and others 1997). 
 
5.1.5.4 Effects on cholesterol synthesis and metabolism 
A feedback control of cholesterol synthesis is demonstrated to occur when 
cholesterol absorption is restricted by plant sterols or stanols (Grundy and others 1969; 
Gylling and others 1999b; Gylling and Miettinen, 1999). When the intestinal absorption 
of cholesterol is greatly reduced, a compensatory increase in the cholesterol synthesis is 
observed. Although intestinal mechanisms are widely accepted as responsible for 
cholesterol lowering actions of plant sterols, animal studies have suggested that intra-
peritoneal and subcutaneous injections of β-sitosterol also lower circulating cholesterol 
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concentrations (Vanstone and others 2001). The mechanism by which β-sitosterol acts 
parenteral is not known. A potential mechanism is that β-sitosterol reduces cholesterol 
synthesis by affecting the activity of HMG-CoA reductase in vitro (Field and others 
1997). In addition, consumption of added β-sitosterol increased the Lecithin-Cholesterol 
Acyl Transferase (LCAT) level in blood (Weisweller and others 1984). Conflicting 
results of the possible effects of plant sterols on enzymes responsible for conversion of 
cholesterol into bile acids (cholesterol-7α-hydroxylase) have been published (Ling and 
Jones 1995). 
 
5.1.6 The effect of the dosage of plant sterols 
Due to the possible mechanisms by which plant sterols are thought to inhibit 
cholesterol absorption, a uniform and intimate mixture of plant sterols with cholesterol 
in the intestine should be important. Thus, the preferred vehicle for plant sterols would 
be dietary fat, which is also a carrier for dietary cholesterol (Mattson and others 1982). 
Large doses of β-sitosterol, up to 3 g/day, are needed to achieve effective reduction in 
serum cholesterol levels (Hallikainen and others 2000b; Hendriks and others 1999). In 
addition to the large doses, the physical properties of free plant sterols and stanols limit 
their applicability in food and oral pharmaceuticals. The cholesterol absorption reducing 
effect of plant sterols seem to be dependent on the physical state of the plant sterols 
(Mattson and others 1982). The clinical trials that showed the largest effects have used 
plant sterols and stanols finely dispersed into foods during cooking or esterified with 
fatty acids and dissolved in vegetable oil (Table 20). Comparison between different 
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studies does not give reliable information on different dosage forms due to large 
differences in study conditions. Esterification of plant sterols increases the lipid 
solubility and thus provides a technically feasible way of introducing plant sterols into 
edible fats and oils (Wester, 2000). In theory, less soluble crystalline plant sterols enter 
the micellar phase less effectively than sterols released from fat-soluble sterol esters 
after their hydrolysis. In the intestine the plant sterol esters are hydrolysed and the 
resulting free sterols decrease the solubility of cholesterol in oil and micellar phases 
 
 
 
 
Table 20-Examples of different dosage forms of plant sterols and stanols in clinical 
trials and the observed serum total cholesterol lowering effectsa 
Formulation Dose/ Day Effect 
β-sitostanol oil suspention 
(25%) in capsules  
3 g No significant 
effect (3 months) 
Β-sitostanol partially dissolved 
and suspended in oil in 
capsules   
1.5 g  15% (4 weeks) 
Plant stanol suspended in food 1.5 g 15% (30 days) 
Plant sterol dispersed (particle 
size 130 µm) in food 
1.25-5.0 g 5% (15 weeks) 
Plant stanol esters in margarine 2.6 g 10% (one year) 
Plant sterol and stanol esters in 
margarine 
0.8-3 g 3-11% (4 weeks) 
Plant stanol esters in margarine 8.6 g 18% (21-28 days) 
    aSource: Christiansen (2002) 
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 (Mattson and others 1977). Only a few comparative studies of free and esterified sterols 
have been performed. In an animal study with rats, no difference in the cholesterol 
lowering effects of free sterols and sterol esters was observed (Mattson and others 1977). 
On the contrary, in a human study where the effect of free β-sitosterol was compared to 
the effect of esterified β-sitosterol, the free sterols resulted in a statistically significant 
9% greater (42% versus 33%) decrease in cholesterol absorption than did the sterol ester 
form (Mattson and others 1982). In that study, both the free and esterified sterols were 
dispersed in food. One possible explanation for the lesser effect of the ester form could 
be incomplete ester hydrolysis in the intestine.  
In a preliminary human study, the efficacy of low dose β-sitostanol administered 
in lecithin micelles showed promising results compared to powdered β-sitostanol as it 
reduced cholesterol absorption by 37% compare to only 11% when lecithin was not 
used. (Ostlund and others 1999b). They suggested that naturally occurring phytosterols 
added with phospholipids might significantly reduce cholesterol absorption. The 
powdered β-sitostanol administered in capsules was ineffective in that study probably 
due to slow dissolution of solid stanol in bile. In another study sitostanol suspended in 
oil at a final concentration of 20% did not show any effect on LDL-cholesterol values 
during a 3-month trial with 3 g sitostanol / day (Denke 1995). 
A preparation of submicron particles of β-sitosterol by precipitation in oil-in-
water emulsion has been described (Sjöström and others 1993), but the cholesterol- 
lowering effect of these sub-micron particles has not been published to our knowledge. 
In a recent study, the cholesterol lowering effect of a pulverized (< 130 µm) plant sterol 
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preparation was rather modest in hypercholesterolemic subjects (Tikkanen and others 
2001). Recently, a study was conducted on a novel hydrophilic phytostanol (FM-VP4) 
composed of sitosterol- and campesterol-ascorbyl-phosphate (Figure 31) provided by 
Forbes Medi-Tech Inc. (Ramaswamy and others 2002). This hydrophilic phytosterol has 
15-fold greater cholesterol inhibition activity than free sterol.  
  
  
 
 
 
Figure 31-Chemical structure of a hydrophilic phytosterol composed of sitosterol- 
and campesterol-ascorbyl-phosphate (Ramaswamy and others 2002). 
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5.1.7 Safety of plant sterols 
Harmful clinical or adverse chemical effects have not been observed in studies 
with human given plant sterols and stanols (Ayesh and others 1999; Plat and others 
1999; Plat and Mensink 2000). In theory, the administration of plant sterols and stanols 
to reduce cholesterol absorption could simultaneously interfere with the absorption of 
fat-soluble vitamins. In practice, reduced serum carotenoid concentrations, but no 
reduced vitamin D and retinol concentrations or α-tocopherol/cholesterol proportion 
have been reported after the administration of plant sterols and stanols (Gylling and 
others 1999a; Gylling and Miettinen 1999; Hallikainen and others 1999; Hendriks and 
others 1999; Westrate and Meijer 1998). 
Several plant sterols of dietary origin have been found in small quantities in 
plasma lipoproteins, human bile, and gallstones (Miettinen and others 1986). In healthy 
subjects, the β-sitosterol concentration in human serum is about 1/1000 of serum 
cholesterol concentration (Kuksis 2001). The consumption of effective doses of β-
sitosterol (0.8-3 g/day) causes even a twofold increase in the serum β-sitosterol 
concentration (Westrate and Meijer 1998). Plant sterols are not recommended for 
normocholesterolemic children under 5 as they need large amount of cholesterol for 
normal development (Berger and others 2004). High serum plant sterol concentrations 
have been observed in patients suffering from sitosterolemia (Miettinen 1980). Very 
high plasma concentrations of β-sitosterol may have potential cytotoxic effects and may 
interfere with cellular functions (Moghadasian and Frohlich, 1999). Similar to 
cholesterol, high plasma plant sterol concentration has been found to be atherogenic 
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(Glueck and others 1991). According to animal studies, it has been suggested that high 
plasma concentrations of plant sterols may have adverse effects on reproductive organs 
(Malini and Vanithakumari 1990, 1991 and 1992; Mellanen and others 1990). In short 
term studies as well as in a long term study that lasted for 1 year, it has been concluded 
that plant sterols, within the range that causes desirable reduction of cholesterol, are 
clinically safe (Berger and others 2004).  
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CHAPER VI 
 
 
MATERIALS AND METHODS: SYNTHESIS OF STRUCTURED 
 PHOSPHOLIPIDS WITH PLANT STEROLS* 
 
 
6.1 Materials 
 
Soybean phosphatidyl choline (PC content not less than 94%) was donated by 
Lipoid GmBH (Ludwigshafen, Germany). β-sitosterol (65% purity) was obtained from 
Fluka Chemie AG (Buchs, Switzerland).The enzyme Phospholipase D (PLD) from 
Streptomyces sp.(Phosphatidylcholine phosphatidohydrolase, EC 3.1.4.4) was donated 
by Ashahi Kasei Corporation (Tokyo, Japan). The activity of enzyme was determined by 
manufacturer as 305 U/mg. Solvents (chloroform and methanol), the matrix (2, 5-
dihdroxybenzoic acid, DHB) and trifluoroacetic acid (TFA) were obtained from Sigma 
Chemical Company (St. Louis, MO). 
 
6.2 Methods 
6.2.1 Phospholipase D (PLD) catalyzed transphosphatidylation reaction 
 Transphosphatidylation reaction. The transphosphatidylation reaction between 
phosphatidyl choline (PC) and β-sitosterol was carried out according to the reaction 
scheme 2 (Figure 32). In a typical reaction, 20 mg of phospholipid and 104 mg of β-
sitosterol (1:10 mol PL/mol sterol) were dissolved in 2 ml of chloroform (HPLC grade)  
_______________________ 
* Part of this chapter is reprinted with permission from Phospholipase-D Catalyzed 
Synthesis of Novel Phospholipid-Phytosterol Conjugates, Hossen M and Hernandez E, 
2004, Lipids, 39 (8). Copyright 2004 by Inform, AOCS. 
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Figure 32- Reaction scheme 2. Phospholipase D (PLD) catalyzed 
transphosphatidylation reaction between phosphatidylcholine and sterol. 
 
 
 
and 100 µl of 0.2M sodium acetate buffer (pH 5.6) containing 40 mM of CaCl2 and 20 
units of PLDP (EC 3.1.4.4) and incubated at 40oC with stirring. 50 µl aliquots drawn 
from the reaction mixture at different time intervals were extracted with 100 µl of  
chloroform/methanol (3:1, by vol.) after adding 50µl of 0.01 N HCl. The lower organic 
layer was separated and further extracted with chloroform and analyzed by TLC analysis 
described above. To confirm the identity of phosphatidyl-sitosterol derivative, a similar 
reaction was carried out between 1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine 
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(DPPC, MW 734.1) obtained from Matreya, Inc. (PA, USA) and β-sitosterol (MW 
414.7). Reaction aliquots collected in chloroform were analyzed by matrix-assisted laser 
desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS). 
TLC analysis. Aliquots collected in chloroform were applied to TLC plates. The 
plates were developed with chloroform/methanol/water (65:25:4 by vol.). Eluted 
compounds were detected by spraying 5% phosphomolybdic acid in ethanol followed by 
heating.  
Time course analysis for the synthesis of PC-sterol. Fatty acid analysis of 
individual bands (PC, PC-sterol and PLD-hydrolysis product) on TLC plates was used to 
quantify the reaction products with time. Preparative TLC followed by GC was used for 
this purpose. About 80 µl of aliquots collected in chloroform was applied on (10cm × 10 
cm) TLC plates and developed as described before. Individual bands were scraped from 
the plates and fatty acid methyl esters were prepared by adding 1.0 ml of 0.25 M sodium 
methoxide in methanol/diethylether (1:1) as mentioned before. After incubation for 5 
min in a water bath shaker at 45oC, 200µl of hexane was added followed by 3 ml of 
saturated NaCl solution. After vortexing and centrifugation methyl esters extracted in 
hexane were collected from upper layer and 1 µl of methyl esters with an internal 
standard (methyl behenate, C22:0 from Nu Chek-Prep, Inc., MN, USA) was injected into 
GC. The initial column oven temperature was 150oC for 3 min and then raised to 210oC 
at 6oC/min and held for 15 min. The injector and detector temperatures were 250oC and 
300oC respectively. The hydrogen was used as carrier gas. The amount of fatty acids 
(mol) in each bands were converted into reaction products (mol) after dividing them by 
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two. The conversion of PC-sterol was calculated as mol% based on their relative amount 
in total phosphatidyl compounds. 
Spectral analysis. To confirm product identities, mass spectra were analyzed 
with a MALDI-TOF mass spectrometer (Voyager, PerSeptive Biosystems, Framingham, 
MA, USA) in a linear mode. This system utilizes a pulsed nitrogen laser, emitting at 337 
nm. The extraction voltage was set at 20 kV and 100 single laser shots were averaged 
for each mass spectrum. For analysis, all samples were dissolved in 0.5 M DHB matrix 
solution in methanol containing 1% trifluroacetic acid. Samples in chloroform (10 µl of 
aliquots) were premixed with the matrix (10 µl) and the sample/matrix mixtures (1.2 µl) 
were directly put on the MALDI-TOF sample plate. Samples were crystallized in air 
without any flow before any spectra were acquired. 
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CHAPTER VII 
 
 
RESULTS, DISCUSSIONS, AND SUMMARY: SYNTHESIS OF STRUCTURED 
 PHOSPHOLIPIDS WITH PLANT STEROLS* 
 
 
 
7.1 Phospholipase D-catalyzed synthesis of phospholipid-phytosterol conjugates 
 
 As a model reaction for monitoring the catalytic activity of PLD, 
transphosphatidylation reaction between glycerol and phosphatidylcholine was carried 
out for 8h according to the conditions mentioned in experimental procedures (Figure 33). 
Synthesis of phosphatidylglycerol (PG) was confirmed by TLC analysis of reaction 
mixture and standard PG obtained from Sigma (St. Louis, MO). Synthesized PG and 
standard PG had similar Rf value (Figure 34). The conversion of PC to PG was almost 
complete as no spot was visible at Rf value similar to standard PC. Enzymatic synthesis 
of PG from PC by transphosphatidylation reaction catalyzed by PLD from savoy 
cabbage has been reported by Juneja and others (1987). Several preparative 
transphosphatidylation reactions between phospholipids and nucleophile alcohols of 
complex structure have also been reported (Takami and others 1994; Rich and 
Khmelnitsky 2001). As PLD catalyzes transphosphatidylation of phosphatidylcholine 
with an acceptor, we proposed that similar reaction can be carried out between 
phosphatidylcholine and sterol (having a hydroxyl group) to synthesize novel  
_______________________ 
* Part of this chapter is reprinted with the permission from  Phospholipase-D catalyzed 
Synthesis of Novel Structured Phospholipid-Phytosterol Conjugates, Hossen M and 
Hernandez E, 2004, Lipids, 39(8), Copyright 2004 by Inform, AOCS. 
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phospholipid-sterol conjugates. We first examined the reaction between natural 
phosphatidylcholine and β-sitosterol by PLD (from Streptomyces sp.) for 24h. Samples 
in chloroform collected at different time intervals were put on TLC plates. A new spot 
having a lower Rf value than that of sitosterol but higher than that of 
phosphatidylcholine was observed on TLC (Figure 35). For structural analysis, similar 
reaction was carried out between DPPC and β-sitosterol for 72 h according to the similar 
reaction conditions mentioned in experimental procedures.  
 
 
 
 
                               
Figure 33- PLD-catalyzed transphospatidylation of PC into PG. 
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Figure 34- TLC analysis of PLD-catalyzed transphosphatidylation of PC into PG. 
 
 
            
Figure 35- TLC analysis of PLD-catalyzed transphosphatidylation of PC into PC-
sitosterol conjugate. Comparing with standard PC and β-sitosterol in all reaction 
products with time, the new unknown spots have Rf value higher than that of PC 
but lower than that of β-sitosterol. 
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The reaction products extracted in chloroform were isolated by silica gel 
(Wacogel C-200) column chromatography followed by TLC analysis (Figure 36). 
Fractions collected with chloroform were identified as sitosterol whereas factions 
collected with chloroform/methanol (24:1 by vol.) had the same Rf value as unknown 
spots observed on TLC analysis of reaction mixture (Figure 32). Fractions collected with 
chloroform/methanol (85/15 by vol.) were identified as PC. Mass spectral analyses of all 
fractions collected were carried out to confirm the structure of DPPC and β-sitosterol 
and identify the structure of phospholipid-sterol conjugate synthesized from DPPC and 
β-sitosterol. Mass spectral analysis of fractions collected with chloroform/methanol 
(24/1 by vol.) confirmed the structure of DPPC-sterol conjugate. The MALDI-TOF mass 
spectrum of this fraction showed a [M-C2H6] ion at m/z 1013, a [M-C3H8] ion at m/z 999, 
a [M-C4H12] ion at m/z 984, and a [M-C7H17] ion at m/z 942 because of the side chain 
fragmentation of sitosterol of DPPC-sterol conjugate (Figure 37). The time course 
analysis of the reaction mixture (Figure 38) indicated that the synthesis of PC-sterol was 
maximum at 12h and then gradually decreased with time. In parallel to 
transphosphatidylation reaction, hydrolysis of PC and PC-sterol was observed and 
increased with time after 12h. The amount of PC decreased with time and the rate was 
much slower after 24 h.  
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Figure 36- TLC analysis of fractions collected from reaction products of PLD-
catalyzed transphosphatidylation of DPPC and β-sitosterol eluted from a silica gel 
column with gradient solvent. DPPC, 1,2-dipalmitoyl-sn-glycero-3-
phosphorylcholine. 
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Figure 37- MALDI-TOF mass spectrum of dipalmityl PC-β-sitosterol. 
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Figure 38- Time course analysis of transphosphatidylation reaction of PC and 
sterol. ♦, PC; !, PC-sterol; ▲, hydrolysis products of phosphatidyl compounds. 
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7.2 Summary 
 
 Phosphatidyl-sterol (PC-sterol) conjugates were synthesized by the reaction of 
PC with sterol by PLD from Streptomyces sp. in a biphasic system of an organic solvent 
with acetate buffer. As it was observed from TLC analysis that the Rf value of 
phosphatidyl-sterol conjugate was less than that of sitosterol, phosphatidyl-sterol 
conjugates will have higher polarity compared to sterols. Such types of phospholipid-
sterol conjugates have not yet been descried in the literature. There is a demand to 
improve efficacy of phytosterols and stanols to reduce total serum cholesterol levels by 
increasing their intestinal bioavailability. As more research need to be focused in this 
area. In our present study we hypothesize that conjugating phytosterols or stanols 
directly with phospholipids will increase their cholesterol lowering efficacy even more. 
Studies to test this hypothesis are required. As commercially available phytosterols, 
phytostanols and their fatty acid esters form are hydrophobic and limited to oil-based 
foods such as margarine, more research in line of our present study are needed to have 
amphiphillic phytosterols with improved food application and absorption aspects.  
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CHAPTER VIII 
 
 
CONCLUSIONS 
 Enzymatic processes were an effective way to produce structured phospholipids. 
Among the four lipases from Mucor miechei (Lipozyme RM IM), Thermomyces 
lanuginose (Lipozyme TL IM), Candida Antarctica (Novozym 435), Rhizopus oryzae 
(Lipase F-AP15), and and phospholipase A2 from Porcine pancreas (Lecitase 10 L),  
only Lipozyme RM IM and Lipozyme TL IM were effective in incorporation of CLA 
into PLs. The maximum incorporation of CLA achieved was 16% with soy 
phospholipids in 72 h. The class of phospholipids had a significant effect on the rate of 
incorporation of CLA compared to source of phospholipids. A three-level, four-factor 
Central Composite Rotatable Design (CCRD) was developed to predict the rate of 
incorporation of CLA into phospholipids . The four factors selected were lipase dosage 
(Ed, wt.% of substrate), substrate ratio (Sr,mol%), reaction time (ti, h) and reaction 
temperature (Te,oC). The enzyme load and substrate ratio had a greater effect on the rate 
of incorporation than did reaction time and temperature. The new phosphatidyl 
derivatives, phosphatidyl-sitosterol, was found to be synthesized by the transfer reaction 
of phosphatidyl residue from phosphatidylcholine to β-sitosterol by Phospholipase D 
from Streptomyces sp. in biphasic medium. Plant sterols were modified to more polar 
lipid class by synthesizing phospholipid derivatives of them. When added to a whey 
protein based oil-in-water emulsion, CLA incorporated structured phospholipids (CLA-
PL) had higher heat stability and oxidative stability compare to the controls. Because of 
phospholipids uses as emulsifier, wetting agent, dispersing agent, baking stabilizer, and 
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liposome former, structured phospholipids with CLA and plant sterols would be unique 
for nutraceuticals and functional food formulations. As it is a challenge to establish the 
most effective but versatile delivery system of functional food ingredients to increase 
their bioavailability. Phospholipids with specific fatty acids and/ or polar head group 
would be efficient dietary fractions to deliver functional components.  
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APPENDIX 
 
 
 
   
Figure A1- Response surface showing the effect of Enzyme load and time with 
temperature and substrate ratio held constant at 55oC and 5.0 respectively. 
 
   
Figure A2- Response surface showing the effect of substrate ratio and temperature with 
enzyme load and time held constant at 55oC and 5.0 respectively. 
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Figure A3- Response surface showing the effect of enzyme load and temperature with 
substrate ratio and time held constant at 5 and 50 h respectively. 
 
 
Figure A4- Response surface showing the effect of temperature and time with enzyme 
load and substrate ratio held constant at 20 (wt.%) and 5 respectively. 
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Figure A5- Response surface showing the effect of enzyme load and substrate ratio with 
time and temperature held constant at 50 h and 55oC respectively. 
 
 
Figure A6- Response surface showing the effect of substrate ratio and time with enzyme 
load and temperature held constant at 20 (wt.%) and 55oC respectively. 
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